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ABSTRACT 
Background: The prevalence of allergy to foods has increased over the last decades and among 
children in Europe as many as 8 % have an allergy to one or more types of food. However, many 
children have received an incorrect diagnosis of food allergy due to shortcomings of available 
diagnostic tests, especially in the case of suspected allergy to nuts or peanuts. Newer diagnostic tools, 
like component-resolved diagnostics (CRD) and basophil activation test (BAT), e.g., basophil allergen 
threshold sensitivity (CD-sens), have shown an improved diagnostic accuracy compared with older 
tests.  
The most severe acute manifestation of allergy, the anaphylactic allergic reaction, is most commonly 
caused by an allergy to peanut or nuts, and there have been no treatments available that might change 
the course of the disease. While disease-modifying allergen immunotherapy has for decades been 
offered as routine practice for the treatment of pollen or house dust mite allergy, severely food-allergic 
patients have had to settle for strict elimination diets and use of emergency medication in case of 
accidental intake. During the past decade, oral immunotherapy (OIT) has emerged as a potential 
disease-modifying treatment for food allergies, but OIT needs to be refined before it can become 
widely implemented. Major limitations of OIT have been frequent allergic reactions and that patients 
with a more severe allergy have a less favorable treatment outcome. The anti-IgE antibody 
omalizumab has been shown to increase the tolerated amount of food allergen among food-allergic 
patients (as long as the treatment continues) and facilitate initiation of immunotherapy in patients with 
severe allergies. 
Objectives: Hazelnut study: To evaluate the new diagnostic tests CRD and CD-sens in children with a 
suspected hazelnut allergy. FASTX study (Food Allergen Suppression Therapy with Xolair
®
): To 
evaluate safety and efficacy of oral immunotherapy with adjuvant omalizumab in severely peanut-
allergic patients.  
Methods: In the study of diagnostic tests for hazelnut allergy, we used CRD to measure IgE antibody 
(ab) levels to the hazelnut components Cor a 1, Cor a 8, Cor a 9 and Cor a 14 in 40 children with a 
doctor’s diagnosis of suspected hazelnut allergy. We also assessed basophil allergen threshold 
sensitivity (CD-sens) to hazelnut and CRD to hazelnut components and compared the concordance of 
these tests to double-blind placebo-controlled food challenge (DBPCFC). In the FASTX study, open-
label omalizumab was given to 23 severely peanut-allergic adolescents, with the aim of increasing the 
amount of peanut they could safely ingest so that OIT could be safely initiated. Omalizumab doses 
were titrated until CD-sens analyses indicated a very low reactivity to peanut allergen stimulation. 
Thereafter, an open peanut challenge was performed, assessing the tolerated peanut dose while on 
omalizumab, and peanut OIT was started the following day. After reaching the maintenance dose of 
10 g of peanuts, the protective omalizumab treatment was phased out with guidance from CD-sens 
and the clinical picture. 
Results: DBPCFC revealed that only 8/40 of the patients with a suspected hazelnut allergy were 
allergic to hazelnuts. The diagnostic accuracy of the new diagnostic tests, CD-sens and IgE-ab to Cor 
a 9 and Cor 14, were far superior to the previously available tests (IgE-ab to hazelnut, Cor a 1 and Cor 
a 8). IgE-abs to Cor a 9 and Cor a 14 were present in all hazelnut-allergic patients; for Cor a 9 the 
median IgE-ab level was 4.5 kUA/l (range 0.7–97.5) among hazelnut-allergic children, compared with 
0.1 kUA/l (range < 0.10–36.2) (P < 0.01) in the hazelnut-tolerant group. The levels of IgE-ab to Cor a 
14 were 5.6 kUA/l (0.9–78.7) for the hazelnut-allergic group and 0.04 kUA/l (< 0.10–13.9) in the 
hazelnut-tolerant group (P < 0.001). 
Median CD-sens among allergic patients was 8.9 compared with 0.05 in tolerant patients (P = 0.05). 
The diagnostic accuracy of CD-sens to hazelnut was maintained in subgroup-analyses where patients 
without IgE-ab to Cor a 9 or Cor a 14 > 0.35 kUA/l were excluded from analyses. 
After omalizumab treatment, all 23 patients passed a peanut challenge of > 3 g of peanuts (median 10 
g) and were started on OIT the following day. Among the 14 patients who went through a peanut 
challenge prior to enrollment, the tolerated dose increased at least 50-fold (median). However, 15/23 
patients needed an increased omalizumab dose in order to accomplish a suppression of CD-sens. All 
23 patients successfully reached the 10 g maintenance dose. After a median of 23 months of OIT, 
11/23 (48 %) of the study subjects had been able to discontinue omalizumab while continuing and 
tolerating OIT and thereafter passing an open peanut challenge. Systemic reactions (n = 43) occurred 
with a frequency of 0.3 % of OIT doses and adrenaline was administered after 0.1 % of the doses. We 
found that successfully treated patients had significantly lower baseline CD-sens and lower IgE-ab to 
peanut and peanut components Ara h 1, Ara h 2 and Ara h 3 compared with patients unable to 
discontinue the protective omalizumab treatment. OIT induced an increase of IgG4-ab to peanut, Ara 
h 2 and Ara h 6 that was significantly higher in successfully treated patients. A substantial proportion, 
6/23 (26 %) of the patients dropped out of the study, mainly due to fear of allergic reactions and an 
abomination for the taste of peanuts. 
Conclusions: CD-sens to hazelnut and component-resolved diagnostics can improve the accuracy 
when diagnosing hazelnut allergy in pediatric patients. CD-sens may further improve the diagnostic 
accuracy in cases when the diagnostic work-up using CRD has been inconclusive. 
The anti-IgE-ab omalizumab can efficiently increase the tolerated peanut dose, which in turn allows 
for a safer practice of peanut oral immunotherapy in severely allergic patients. 
Peanut oral immunotherapy induces an increased tolerance to peanuts; the increased tolerance is at 
least partially explained by the production of protective allergen-specific antibodies of IgG4-subtype. 
Despite the increased tolerance, allergic reactions continuously occur during pOIT. We need to find 
ways to minimize this major limitation before OIT can be widely implemented; development of 
hypoallergenic OIT preparations, use of immune stimulatory adjuvants and improved patient selection 
might help in accomplishing a safer and more effective treatment. 
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  1 
1 INTRODUCTION 
Food allergy is a major health concern, affecting as many as 8 % of children.
1,2
 The prevalence of 
allergy to peanuts or nuts (and food allergy in general) seems to be increasing
3-5
 and unlike allergies to 
cow’s milk6 or hen’s egg,7 peanut and nut allergies are seldom outgrown.8,9 Peanuts and nuts are the 
most common triggers for anaphylaxis among children.
10
 
Food allergies are most often IgE-mediated. An allergic reaction might take place when an IgE-
sensitized individual
11
 (someone who has IgE antibodies capable of binding one or several allergens) 
encounters an allergen
12
 (usually a protein) that the IgE antibodies can recognize and bind to. 
However, far from all sensitized individuals experience symptoms upon allergen exposure.
13-15
 This 
can partially be explained by the fact that the ability to induce an allergic reaction differs from one 
allergen to another. Within an allergen source, such as the hazelnut, there are several allergens
16
 of 
which some, like the highly stable seed storage protein Cor a 14, are known to be highly capable of 
inducing allergic symptoms,
17
 in contrast to the birch pollen-related hazelnut protein Cor a 1.
15,18
 
Traditional diagnostic tests, the skin prick test and analysis of IgE-ab to an allergen source, cannot 
discriminate between test results which are positive due to sensitization to a highly potent allergen like 
Cor a 14 and those positive due to sensitization to Cor a 1. Over the years, many patients have 
received an inaccurate diagnosis of being allergic.  
New diagnostic tests, like component-resolved diagnostics (CRD) and basophil activation test (BAT), 
have improved the diagnostic accuracy. In CRD, IgE-sensitization to individual allergens is detected, 
as opposed to the traditional tests, which detect presence of IgE antibodies against any of the proteins 
(both those of high and low clinical importance) within the allergen source.
19
 In BAT, basophilic 
granulocytes, one of the two most important effector cell types for IgE-mediated allergy (mast cells 
being the other), are stimulated with allergen extracts in vitro. Basophils that react with degranulation 
upon allergen stimulation can be detected through flow cytometry. Basophil allergen threshold 
sensitivity, CD-sens,
20
 is a BAT method where the cells are stimulated with an allergen at several 
concentrations. CD-sens discriminates peanut-allergic from peanut-sensitized but tolerant patients 
with high accuracy,
21,22
 and can be used to monitor treatment effect in allergen immunotherapy.
23,24
 
Subcutaneous allergen immunotherapy (SCIT) has been used as a treatment for pollen allergy for over 
a century
25
 and more recently for other allergies, such as insect venom allergy.
26,27
 It is long since 
established as efficacious in causing symptom relief (e.g., in pollen allergy) and preventing 
anaphylaxis (in venom allergy).
26,28,29
 However, there have not been any approved disease-modifying 
treatments for patients suffering from food allergies; SCIT has been tried for peanut allergy, but severe 
adverse events (AEs) occurred frequently.
30,31
 In the last 15 years, oral immunotherapy (OIT) has 
emerged as a potential therapy for food allergies.
32,33
 Short-term outcomes of OIT are generally 
good.
33,34
 The downsides of OIT are that most subjects experience adverse events,
35
 that protection 
seems to vanish if OIT is stopped, even after years of treatment
35
 and it seems that OIT is less 
effective in patients with severe allergies and high IgE-ab levels.
34-36
 
An anti-IgE antibody, omalizumab, approved for the treatment of allergic asthma, has been shown to 
increase the tolerated dose of peanuts among peanut allergic subjects.
37,38
 When combined with OIT, 
omalizumab has been shown to facilitate OIT by reducing AEs and allowing for faster up-dosing of 
OIT.
36,39,40
 
This thesis aimed to evaluate the newer diagnostic tests CRD and CD-sens in patients with a suspected 
hazelnut allergy. We also aimed to provide and evaluate omalizumab-facilitated peanut oral 
immunotherapy among severely peanut-allergic adolescents. 
  3 
2 BACKGROUND 
2.1 FOOD ALLERGY 
Food allergy is a common disorder; exactly how common depends on geographic location, how the 
disorder is defined and how it is measured. It is estimated that up to 8 % of children in Europe and 
North America are allergic to some kind of food.
1,2
 
2.1.1 Definition 
Food allergy can be defined as “an adverse health effect arising from a specific immune response that 
occurs reproducibly on exposure to a given food.”41 It could be argued that this definition is not 100 % 
accurate, e.g., when it comes to reproducibility. 
In contrast, food intolerance has a non-immune-mediated pathophysiology. Symptoms in such 
disorders could be due to metabolic causes, such as lack of enzymes in lactose intolerance
42,43
 or 
glucose-6-phosphatase dehydrogenase deficiency (favism),
44
 pharmacological causes, as in sensitivity 
to biogenic amines,
45
 or unknown causes. 
2.1.2 Classification of food allergy 
Food allergy is commonly classified into IgE-mediated and non-IgE-mediated food allergy, but can be 
caused by both immunologic mechanisms at once. IgE-mediated food allergies are far more common 
(especially in the case of nut or peanut allergy) and will be discussed in detail in this thesis.  
The non-IgE-mediated food allergies include diseases such as celiac disease,
43
 FPIES
46
 (food protein-
induced enteropathy syndrome), Heiner’s syndrome,47 eosinophilic esophagitis and eczema, where T-
cells have a major role in the development of symptoms. However, for eczema, IgE is sometimes 
involved in the pathophysiological process,
48
 and IgE-abs might also be involved in the 
pathophysiology of eosinophilic esophagitis and Heiner’s syndrome, at least for a subset of patients. 
2.1.3 Epidemiology 
Exact and consistent prevalence figures for food allergy are hard to find, as they vary by geographic 
location, age, and diagnostic criteria.
1
 A 14.5 % point prevalence of self-reported food allergy has 
been reported for northern Europe as compared with 3.5 % for southern Europe, while only 1.6 % and 
1.8 % respectively had a positive skin prick test result to the corresponding food.
49
 In a population-
based cohort of children aged 7–8 years from northern Sweden, the parent-reported prevalence of food 
allergy and food hypersensitivity was 21 %, Strinnholm et al. 2006.
50
 In the same cohort, the 
prevalence of self-reported allergy to milk, egg, wheat or cod at age 12 years was 4.8 %. About 1/3 
(1.4 % of total) received a doctor’s diagnosis of food allergy after clinical evaluation (including 
laboratory work-up) and in 1/6 (0.6 % of total) the allergy was confirmed by the gold standard double-
blind placebo-controlled food challenge.
51
  
The prevalence of food allergy has increased over the last decades and recent reports suggest that the 
prevalence might be as high as 8 % among children.
1-3,52-54
 In the pediatric population, the most 
common food allergies are to milk or egg, followed by allergy to wheat, peanuts and or tree nuts.
55,56
  
Peanut allergy is the most common “nut” allergy. As stated above, exactly how common it is depends 
on the population studied and how it is defined, but the average pediatric prevalence seems to be 
 4 
around 2 % in Western countries.
13,57
 Prevalence might be higher among Swedish children; in the 
Stockholm-based BAMSE cohort,
58
 as many as 5.9 % of the 8-year-olds had both self-reported peanut 
allergy and IgE-sensitization, although cross-reactivity from birch pollen allergy probably explains 
both symptoms (oral allergy syndrome) and sensitization in some individuals. Epidemiologic data on 
tree nut allergy is inconsistent; in a recent systematic review
59
 of 36 studies the “probable tree nut 
allergy prevalence” ranged from 0.05 % to 4.9 % (combination of one or more of the following: 
history, laboratory tests and doctor’s diagnosis). The most common tree nut allergy in Europe is 
hazelnut allergy, whereas allergies to walnut or cashew are more common in the US. 
When it comes to the most severe type of allergic reaction, anaphylaxis, Vetander et al. estimated that 
peanuts cause 19 % of food-induced anaphylaxis among Swedish children. Tree nuts as a group also 
caused 19 % of anaphylaxis (cashew nut 8 %, hazelnuts 2 %). In comparison, egg or milk was the 
eliciting food in 12 % and 6 % of cases, respectively, and in 23 % of cases, the eliciting food remained 
uncertain.
10
 
2.1.4 Pathophysiology 
The immune system is a very complex and tightly controlled system. It protects us against a wide 
range of harmful and potentially lethal threats such as bacteria, viruses, and malignantly transformed 
cells, by attacking and killing them.
60
 At the same time, a well-regulated immune system stays tolerant 
of its host (in other cases, auto-immune diseases may develop) and of non-harmful substances, such as 
foods.
61
 Allergies are a consequence of a dysregulated or maladaptive immune system that reacts in an 
undesired manner upon exposure to allergens. 
An imbalance between cytokines produced by T-helper (Th) cells type 1 and 2, with an excess of Th2 
cell cytokines, has been one of the main explanatory models of the development of food allergy. The 
shift to Th2-dominance leads to an increased production of IgE-type abs, as well as pro-allergenic 
cytokines such as IL-4, IL-5, and IL-13.
62
 The reason for this imbalance is thought to be 
multifactorial. Environmental factors such as exposure to cigarette smoke,
63,64
 pollutants,
65
 microbial 
exposure,
66
 timing of introduction of solid foods,
67,68
 allergen exposure, including through which route 
exposure occurs: oral vs. dermal,
69,70
, lifestyle,
71
 and lastly, but very importantly, hereditary factors 
and other atopic diseases, such as eczema (the atopic march), all affect the risk of becoming food-
allergic.
72-74
 The Th1-Th2 imbalance, or this imbalance in combination with the above mentioned 
factors, is thought to induce B-lymphocytes to produce IgE-abs instead of other classes of Ig-abs. 
When an individual has developed IgE-abs directed against an allergen, he/she has become 
sensitized.
11
 
2.1.5 The IgE-mediated allergic reaction 
The IgE produced by a sensitized individual can be found both as free IgE-abs in the circulation and 
as IgE-abs bound to target cells like basophilic granulocytes (in blood) or mast cells (in tissues). When 
the sensitized individual’s immune system encounters the allergen, an IgE-mediated reaction might 
take place. In order to activate the mast cells or basophils, the allergen has to cross-link IgE-abs, 
bound to high affinity FcεRI receptors.75 If enough crosslinks (hundreds to thousands) have been 
established, an intracellular signal is produced, strong enough to activate the cells.
76
 The activation 
leads to a series of events eventually leading to degranulation, which in turn leads to the release of 
histamine, tryptase, carboxypeptidase, and other mediators that cause allergic symptoms such as 
erythema, hives, bronchoconstriction, and rhinitis.
11
  
  5 
2.1.6 Allergens and cross-reactivity 
Allergic reactions are elicited by allergens. Accordingly, allergens are molecules/substances/antigens 
that may induce allergic reactions and to do so, the allergens have to be able to bind and cross-link 
IgE-abs (for IgE-mediated allergies).
77
 Most allergens are also capable of inducing production of IgE-
abs specific for the antigen, i.e., they have the ability to sensitize.
11
 Allergens are almost exclusively 
proteins, and although many proteins are capable of inducing an allergic response, some are far more 
likely to cause allergies. These common allergens share features such as: many epitopes (binding 
sites) for IgE-abs, similar molecular weights, and resistance to degrading enzymes and heat.
78,79
  
Cross-reactivity can occur, as allergens from different sources can be so homologous that IgE-abs 
produced in response to exposure to one allergen can bind to other similar allergens from other 
sources. An example of high relevance is hazelnut and birch pollen cross-reactivity: The main allergen 
of birch pollen, Bet v 1,
80
 is a PR-10 protein (pathogenesis related protein 10) that is homologous to 
and has similar epitopes as the Cor a 1 protein (also a PR-10) in hazelnuts. Hence, an IgE-ab targeted 
for birch pollen also has the potential to bind (cross-react) to this hazelnut protein.
81
 These cross-
reactive IgE-abs are not as capable of inducing allergic reactions, since their capacity to bind and 
cross-link IgE-receptors on basophils and mast cells is not as strong as IgE-abs from primary 
sensitization. Also, Cor a 1 is unstable. Thus, digestion by saliva and gastric fluid and/or cooking 
degrades Cor a 1 which alters the epitopes’ micro-structures so that they are no longer able to attract 
Cor a 1 IgE-abs.
82
 This explains why a person with birch allergy who gets oral pruritus when eating 
raw hazelnuts can usually eat processed hazelnut without experiencing problems with oral symptoms.  
2.2 NUT AND PEANUT ALLERGY DIAGNOSTICS 
A thorough patient history is imperative in the diagnostic work-up of suspected food allergy. There 
are today several ways to diagnose food allergy, with a trade-off between costs and quality (Figure 1). 
To confirm a diagnosis of IgE-mediated allergy, or when patient history is not enough, an allergy test 
such as the skin prick test (SPT) or measurement of circulating IgE-abs in the blood is usually the first 
diagnostic step. Such tests can easily identify IgE-sensitized individuals, but unfortunately they are not 
as good at diagnosing food allergy adequately.
18,41
 The discrepancy between sensitization (measured 
with SPT or specific IgE-abs) and allergic symptoms is aggravated when diagnosing allergy where 
cross-reactivity is common, e.g., diagnostics of nut allergies in the Nordic countries where birch 
pollen allergy is common.
83
 The gold standard for diagnosing food allergy, the double-blind placebo-
controlled food challenge, is expensive and associated with risks.
41
 Therefore, improved diagnostics 
tools like component-resolved diagnostics and basophil activation tests are much needed.  
 
Figure 1. Inside pyramid: food allergy diagnostic tests. To the left: what these tests measure.  
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2.2.1 Skin prick test 
SPT is a rapid and safe allergy test that allows for testing of one or more allergens simultaneously. 
The allergen is usually in the form of an extract. A drop of this solution is placed on the patient’s skin 
(usually on volar side of the forearm) and the skin is thereafter superficially punctured with a small 
needle. In the presence of allergen-specific IgE-abs bound to mast cells in the skin the allergen might 
cause a local reaction of a wheal and flare (usually measured after 15 minutes) that is compared with 
negative (saline) and positive (histamine) controls.
84
 A positive test is evidence of the patient being 
sensitized to the allergen, but the correlation to clinical allergy varies from one allergen to another and 
also with the size of the wheal.
85
 Wheal sizes might also differ depending on who is performing the 
test
86
 and on the extract being used.
18
 False negatives do occur,
18
 but in general the major drawback of 
SPTs is the low specificity (false positives).
84,87,88
 
2.2.2 Allergen-specific IgE-abs 
The presence of allergen-specific IgE-abs (or cross-reacting IgE-abs) is a prerequisite for the IgE-
mediated allergic reaction to take place. IgE-abs are today easily measured in vitro, as commercial 
tests are available for many allergens. The tests use the ELISA method (enzyme-linked 
immunosorbent assay) to detect IgE-abs capable of binding the allergen of interest. Briefly, the 
allergen is bound to a solid phase and the patient’s serum (or blood) is added. After incubation, when 
IgE-abs can bind to the allergen, the serum is washed away, leaving only allergen-bound IgE-abs. 
Anti-IgE molecules with fluorescent markers are then added, the sample is washed again, and 
thereafter the amount of allergen-bound IgE-abs is measured through spectrophotometry.
89
 Like in the 
skin prick test, a positive test is not equivalent to allergy. This is partly due to the fact that an 
allergenic food often consists of many proteins, which in theory can serve as allergens. Both 
measurement of IgE-abs and SPT demonstrate presence of IgE-abs to any of these proteins within the 
allergen; however, some of these proteins are unstable and/or have lower ab-affinity due to secondary 
sensitizations as in the case of cross-reactivity to, e.g., birch pollen.
13,83
 Also, monovalent allergens are 
capable of binding one IgE molecule each, which may result in a positive test result, even though 
monovalent allergens cannot achieve the cross-binding of several IgE-abs required to activate 
basophils and mast cells. 
2.2.3 Component-resolved diagnostics (CRD) 
By separating, purifying, and identifying the different allergens within an allergen source it is possible 
to analyze IgE-abs to individual proteins within an allergen source instead of analyzing IgE-ab levels 
to whole allergens. These different allergens/proteins are the “components” in “component-resolved 
diagnostics,” a term coined by Valenta et al. in 1999.19 IgE-sensitization to the components is 
measured using the same methodology as in allergen-specific IgE-ab testing.  
The components’ names derive from their Latin names (genus and family). Taking hazelnut as an 
example: hazelnut has the Latin name Corylus avellana: the hazelnut proteins are named “Cor a” 
followed by a number, e.g., Cor a 1 and Cor a 14, while examples of peanut (Arachis hypogaea) 
components are Ara h 2 and Ara h 8.  
By looking at sensitization patterns to different allergens within an allergen source, diagnostic 
accuracy can be improved. There is now rapidly increasing knowledge of which IgE-sensitization 
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patterns to certain proteins that are associated with allergy and, vice versa, which sensitization patterns 
that are associated with cross-reactivity to e.g. pollen.  
Patients sensitized to PR-10 proteins only (Cor a 1, Ara h 8) have a high likelihood of being tolerant to 
hazelnut and peanut, respectively.
83,90
 In nut and peanut allergy, it has been established that 
sensitization to proteins from the 2S albumin, 7S albumin and 11S globulin protein families are highly 
associated with clinical allergy.
17,91
 These seed storage proteins are highly resistant to heat and 
enzymatic degradation and hence remain largely intact when they come in contact with the patients’ 
immune system. They do not cross-react with major aeroallergens such as birch or timothy, thus 
making a false-positive test result less likely. Taking peanut as an example, sensitization to the 2S 
albumin protein Ara h 2 has in several studies been shown to correlate excellently with clinical allergy 
to peanut.
21,92
 By combining this information on component (protein) properties with the patient’s 
sensitization pattern to these individual components, diagnostic accuracy can be improved.
15,92
 The 
increased diagnostic accuracy achieved using component-resolved diagnostics has proven more 
beneficial when diagnosing food allergies from the plant kingdom than for animal products,
93
 e.g., 
peanut
13,21,91,94,95
 and nut allergy, hazelnut,
15,17,90,96
 cashew,
97-100
 walnut,
101
 and soy.
102,103
 Still, 
component-resolved diagnostics is far from perfect and even with moderately elevated IgE-ab titers to 
storage proteins, such as Ara h 2 in peanut or Cor a 9 and 14 in hazelnut, we still find patients tolerant 
to the tested food.
104
 Thus testing and interpreting test results should always be carried out in the light 
of patient history. 
2.2.4 Oral food challenge (OFC) 
The double-blind placebo-controlled food challenge is the gold standard for diagnosing food allergy.
41
 
OFCs should be carried out by experienced staff in a hospital setting, since clinical evaluation of 
symptoms at OFCs is often difficult and severe reactions requiring emergency room treatment do 
occur.
105
 Usually, the food is given in very small amounts (milligrams) and stepwise escalated every 
30 minutes until doses of several grams are reached. Rarely, in case of certainty of tolerance, single 
dose OFC of several grams of the food can be given right away. When diagnosing food allergies, and 
in research, the double-blind placebo-controlled food challenge (DBPCFC) is preferred in order to 
minimize the impact of psychological effects.
106
 However, since health care resources are often 
limited, open food challenges are more common. 
2.3 BASOPHIL ACTIVATION TEST 
Basophils and mast cells initiate the IgE-mediated allergic reaction, thus making them interesting 
targets for allergy diagnostic tests. While mast cells are mainly localized in tissue and thereby hard to 
harvest for in vitro analysis, basophils are readily available in blood.
11,107
 
When IgE-abs bound to high affinity FcεRI receptors on mast cells/basophils are stimulated with 
antigens in large enough quantities, the basophils react by secreting mediators such as histamine, 
tryptase, carboxypeptidase and IL-4, which are released into the tissue or blood stream.
108
 While 
tryptase, for instance, is known to be released from basophils and mast cells in severe allergic 
reactions, the tryptase levels correlate poorly with the severity of the allergic reaction, especially in 
children.
90
 There are several ways of effectively measuring basophil activity to an allergen which all 
go under the name basophil activation test (BAT) or similar, but they vary when it comes to 
methodology. Basophils can either be stimulated with different dilutions of the allergen of interest, 
rendering the basophils’ “allergen sensitivity” as in the CD-sens method,109 or they can be stimulated 
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at a single concentration, revealing the reactivity, i.e., how strongly these basophils react at a given 
concentration.
110,111
 
BAT as a method utilizes flow cytometry to detect basophils, and CD203c is commonly used as a 
marker for identifying basophils.
112
 When basophils are activated, granules containing, e.g., histamine 
are released from the cell. The same granules also contain CD63; histamine release and CD63 cell 
surface exposure occur simultaneously.
113
 In contrast to histamine, CD63 remains on the cell surface 
and by using flow cytometry, activated CD63-positive basophils can be identified. The ratio of 
CD203c/CD63 double positive cells (identified using flow cytometry) to CD203c single positive cells 
gives us the percentage of basophils that are activated by the stimulation. 
2.3.1 CD-sens 
Basophil allergen threshold sensitivity, CD-sens, is a BAT method where basophils from peripheral 
blood are stimulated with several (usually 8–10) allergen concentrations. Since it is a test performed 
on whole blood, serum components like antibodies and cytokines will be present, which might 
influence the basophils’ sensitivity, just as they would in vivo. Like an oral food challenge, the CD-
sens method will not only provide a dichotomous positive/negative result, but also provide 
information on how sensitive the basophils are to the allergen. The CD-sens value is calculated as 
follows: the eliciting allergen dose that induces 50 % (ED50 %) of maximum CD63 % upregulation of 
the dose-response curve is identified. ED50 % is then inverted and multiplied by 100. Hence, the 
higher CD-sens value, the more sensitive the basophils are to this particular allergen (Figure 2).
109
 
 
Figure 2. The allergen concentration that elicits a 50 % of maximum CD63 % upregulation (ED50 %) is calculated 
from the dose-response curve. CD-sens= the inverted ED50 % x 100. Adapted (with permission) from Nopp A.109 
2.3.2 Allergen-binding activity (ABA) 
CD-sens is usually performed on whole blood samples, but it can also be performed in a sample where 
the plasma has been washed away, leaving only blood cells in the sample. When the plasma-depleted 
washed CD-sens value is higher than the whole blood CD-sens, there is an indication of the presence 
of factors that interfere with the allergic reaction. The magnitude of this blocking effect can be 
demonstrated as the ratio between the washed CD-sens and the whole blood CD-sens, named ABA 
(allergen-binding activity) by Johansson, Nopp et al.
109
 ABA is induced in successful allergen 
immunotherapy
35,114
 (AI), hence ABA can be used as a marker when assessing the efficacy of AI.
23,24
 
  9 
2.3.3 Clinical implications for CD-sens 
Many cases of food allergy or suspected food allergy are not hard to diagnose correctly for a trained 
allergist with the help of SPT and/or IgE-ab measurements, especially as we are now routinely using 
CRD (component-resolved diagnostics). But in a subset of patients there might still be doubts as to 
whether a positive sensitization test is due to cross-reactivity or is indicative of a more severe allergy 
(even after CRD). A food challenge would then be the most appropriate diagnostic investigation, but 
might not be feasible. In the diagnostic work-up of idiopathic anaphylaxis in poly-sensitized 
individuals numerous food challenges might be needed. In situations like this, CD-sens could be a 
useful diagnostic test. Basophil allergen threshold sensitivity correlates very well with the outcome of 
DBPCFC in patients with a suspected peanut allergy.
21
 In addition to distinguishing between tolerant 
and allergic patients, the CD-sens method might be able to grade the severity of peanut allergy,
115
 
although confirming studies are needed. CD-sens can be analyzed for virtually any allergen, provided 
that suitable allergen extracts are available. CD-sens can also be used in the diagnostic work-up of 
patients with allergic asthma and allergic rhinitis, as it has been shown to correlate significantly with 
both nasal and bronchial allergen challenges.
116
 
As described, CD-sens is useful when monitoring immunotherapy. In allergen immunotherapy IgE-ab 
levels tend to increase initially, making tests based on IgE-ab detection unsuitable for following 
treatment effect.
117
 In anti-IgE treatment with the monoclonal antibody omalizumab, traditional IgE 
measurements cannot be used. IgE-ab levels in serum increase during omalizumab treatment since 
omalizumab binds free IgE-abs resulting in IgE-omalizumab complexes with a longer half-life 
compared with free-IgE.
118
 In omalizumab-treated patients, suppressed basophil allergen sensitivity 
correlates with a highly increased clinical tolerance.
23,109
 
2.3.4 Summary of nut and peanut allergy diagnostics 
The need for diagnostic methods varies from case to case; sometimes there is no need of any tests or a 
skin prick test or serum IgE-ab test is sufficient, while other cases call for new and more advanced 
tests or food challenges. Figure 3 illustrates key factors in IgE-mediated allergic reactions. It also 
illustrates where the previously mentioned allergy diagnostic tests are used. 
 
Figure 3. IgE-sensitized individuals do not necessarily experience symptoms upon contact with the allergen. Several 
factors, like allergen dose, grade of sensitization, presence of blocking antibodies, overall state of the individual at that 
time etc. will all have an impact on the clinical outcome after allergen exposure. The left column lists diagnostic tests, 
arrows indicate where, in this chain reaction, the effect that the test is measuring is found. The further down in the 
figure the test is found the better - at least in theory. Dotted lines indicate indirect assessment of allergen stability and 
affinity (based on experience at a population level or a pre-clinical level). Skin prick test is not included in this figure; in 
theory it measures a mediator effect on the target organ, but in reality it is about as accurate as IgE-ab analyses.  
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2.4 TREATMENT OF FOOD ALLERGY 
Until recently and before the studies within this thesis were planned and carried out, there was no 
approved disease-modifying treatment for food allergy. However, the European Academy of Allergy 
and Clinical Immunology (EAACI) recently published guidelines stating that allergen immunotherapy 
might be considered for carefully selected patients at specialized centers.
119
 Prior to these guidelines 
(and even now, for the majority of patients), avoidance, emergency medication in case of accidental 
exposure, and patient education are recommended. In case of mild food allergies, this might be 
enough. But for many patients, their allergy is a considerable disability. Always facing the risk of 
having severe allergic reactions leads to significant negative effects on quality of life for the patients 
and their relatives. Few are aware that children with severe food allergy rank their quality of life as 
worse than children with diabetes.
120-122
 Considering the fact that nut/peanut allergy is rarely 
outgrown,
8,9
 it is obvious that there is a need for new treatment options. 
2.4.1 Allergen immunotherapy 
Allergen immunotherapy (AI) is a treatment of a specific allergy that is carried out by presenting one 
(or a few) specific allergen(s) to the patient’s immune system in gradually increasing doses. AI is 
generally thought to be allergen-specific and hence does not affect allergies other than the one for 
which the subject receives treatment. However, Thyagarajan et al. showed that egg- and peanut-
allergic children treated with peanut OIT had significantly lower basophil activation upon stimulation 
with an egg extract after OIT than before OIT was started.
123
  
2.4.2 Sub-cutaneous immunotherapy 
The most widespread and studied form of AI is subcutaneous immunotherapy (SCIT). SCIT has been 
used as a treatment for pollen allergy for more than a century
25
 and is now also used for insect venom 
allergies and perennial allergies against, e.g., cat and  house dust mite; it is efficacious, safe and cost-
beneficial.
28,29,124,125
 However, in trials of SCIT for food allergy (peanut), frequent severe adverse 
events were observed, including one fatality.
30,31
 Several routes of administration have been tried for 
food allergy AI: sub-lingual (SLIT), epicutaneous (EPIT), and oral (OIT), all described below, and 
rectal,
126
 not further discussed. 
2.4.3 Oral immunotherapy 
Oral immunotherapy (OIT) is a type of AI in which the allergen is ingested. The basic concept is to 
give the allergen in gradually increasing doses as the patient’s tolerance increases. Although 
experimental use of OIT has increased explosively over the last decade, it is not an entirely new 
concept. The first successful case report of treatment of an egg-allergic boy dates back over a 
century
127
 and, in a case series from the 80s where 19 patients were treated mainly for egg or milk 
allergy, treatment success was reported in 14/15 cases adhering to the treatment protocol.
128
 
In 2009, Jones et al. reported results from their OIT study of peanut-allergic children
33
 (age 1–10 
years), starting with 1 mg of peanut protein and then increased (if tolerated) to a maximum of 300 mg. 
A peanut challenge was performed after 4–22 months. At this challenge, 27/29 patients ingested 1.8 g 
peanut protein (cumulative dose 3.9 g) resulting in a treatment success rate of 93 % per protocol or 69 
% by intention to treat. However, many of these patients, 38 %, had objective symptoms and were 
treated with antihistamines. Blumchen et al. found that 14/23 children (5–14 years) with a 
predominantly severe allergy to peanuts were able to reach a maintenance dose of at least 125 mg of 
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peanut protein (range 125–500 mg). OIT was then stopped for two weeks and followed by a DBPCFC 
to peanut where the subjects tolerated a median dose of 250 mg.
129
 Making a fair comparison of these 
two studies, and the studies that followed, is not easy since study populations differ in terms of age 
and allergy severity, and the definitions of successful treatment also differ. In the Jones study, the 
patients ingested higher doses of peanut, but not all patients tolerated these doses. In the Blumchen 
study, OIT was withdrawn for two weeks prior to food challenge, which is known to be associated 
with fewer patients being tolerant to the food in the following food challenge.
35,36,130
 
In the first published placebo-controlled study of peanut OIT, 16/19 patients reached the maintenance 
dose of 4 g peanut protein. In this study, the initial doses were low, perhaps explaining that fewer 
patients dropped out. At the following DBPCFC, all 16 patients ingested a cumulative dose of 5 g of 
peanut protein (~20 peanuts), with only one of them needing treatment with antihistamine. The 
placebo group ingested a median dose of 280 mg of peanut protein, 3/9 patients were treated with 
epinephrine.
131
 The patients in the Jones study
33
 continued with OIT after the DBPCFC (follow-up 
study
35
) until their peanut-specific IgE dropped < 2 kU/l. Then, OIT was stopped for one month, 
followed by a DBPCFC at which 5/5 patients passed a 5 g peanut protein challenge. The protocol was 
then changed: symptom-free patients with peanut IgE of < 15 kU/l underwent the same challenge and 
7/8 passed. Finally, all patients who had been on OIT for five years (but had peanut IgE > 15 kU/l) 
went through a DBPCFC and, interestingly, only 1/12 (8 %) passed after being off OIT for 1 month. 
Still, the cumulative dose among patients not passing this food challenge was quite high, > 3 g on 
average.
35
 This study also provided interesting information on baseline data associated with successful 
outcomes; the strongest predictor was low levels of peanut IgE-abs/total IgE ratio and peanut IgE-abs. 
Low Ara h 2 IgE-ab levels just before the final peanut challenge were associated with a favorable 
outcome; similar predictive laboratory data were also observed in a milk OIT study by Wood et al.
36
  
The largest peanut OIT study to date is the STOP II study by Anagnostou et al.
34
 This was an open 
placebo-controlled study of British children (1–16 years) with a peanut allergy of any severity. 
Treatment success was 49 %, measured as passing a 1.4 g peanut protein challenge after six months of 
OIT. In the placebo group, no patients passed the food challenge.  
A double-blind study comparing peanut OIT/SLIT was carried out by Narisety et al.
132
 They treated 
21 peanut-allergic children (7–13 years) with active OIT plus placebo-SLIT or placebo-OIT plus 
active SLIT. After six months, threshold doses had increased, in median, from 21 mg to 496 mg in the 
active SLIT group and from 21 to7,246 mg for active OIT. Thus OIT-treated patients tolerated more 
than ten times higher doses than the SLIT-treated children. After 12 months, patients tolerating less 
than 5 g continued with a combination of SLIT and OIT, while patients tolerating 5–9 g continued 
with monotherapy (only OIT cases) for six months. This study also evaluated sustained 
unresponsiveness in the ten patients who passed a final food challenge of a cumulative dose of 10 g 
peanut protein. Here, a new challenge was performed after four weeks off therapy, where only 4/10 
passed. In contrast, SLIT appeared to be safer and better tolerated and 9/10 patients in this group 
stayed in the study during the whole blinded phase, compared with 7/11 in the OIT group. 
2.4.4 Sub-lingual immunotherapy 
In SLIT, small doses of the allergen are placed under the tongue where it is presented to the local 
immune system. It seems that SLIT is not as effective as OIT,
132
 the main reason probably being that 
only a limited dose can be administered. On the other hand, it seems to be better tolerated than 
OIT,
132,133
 probably due to lower doses and administration in a tolerant body part (oral cavity), where 
 12 
basophils and mast cells are not as common.
61
 In a double-blind placebo-controlled study by Fleischer 
et al.,
134
 40 peanut-allergic patients (12–37 years old) were given either peanut SLIT or placebo SLIT 
for ten months, followed by a peanut challenge. A total of 70 % in the active group increased their 
highest tolerated dose at least ten-fold, compared with baseline; the median increased from 3.5 mg to 
496 mg. In the placebo group, 15 % had a ten-fold increased threshold dose. Mostly mild allergic 
symptoms were reported for about 37 % of doses given, non-oropharyngeal symptoms were reported 
for about 7 % of administered doses. After this, the placebo patients crossed over to the active group. 
The whole study lasted three years, but 50 % dropped out. After three years, four patients were fully 
desensitized to 10 g of peanut. They were taken off therapy for eight weeks and then re-challenged. 
All of them, 10 % of the initial study population, passed this re-challenge and had thus achieved 
sustained unresponsiveness (SU).
133
 
2.4.5 Epicutaneous immunotherapy 
In EPIT, allergen presentation happens through the skin by usage of allergen-containing skin patches. 
In 2010, a blind placebo-controlled study showed that EPIT is a well-tolerated treatment for cow’s 
milk allergy with tendencies towards increased tolerance (not significant).
135
 In a study of peanut EPIT 
with patches containing 50, 100, and 250 µg of peanut protein or placebo there was a significant 
difference between the 250 µg and placebo patch in achieving a ten-fold increase in tolerated peanut 
dose in a sub-group of children aged 6–11 years, while there was no significant difference among 
adolescents/adults.
136
 
2.4.6 Omalizumab 
Omalizumab is a drug developed and approved for treatment of severe allergic asthma and chronic 
spontaneous urticaria. Its active substance is humanized monoclonal anti-IgE-abs of IgG-type. 
Omalizumab is administered as sub-cutaneous injections every second to fourth week and the dosage 
is based on total IgE-level and body weight.
137
 Omalizumab only binds free circulating IgE and binds 
the Fc-part of the IgE-molecule, the same part of IgE-abs that binds to the FcɛRI on target cells.138 As 
a result, IgE bound to omalizumab cannot bind to the FcεRI receptors on mast cells or basophilic 
granulocytes. The declining amount of free IgE leads to a downregulation of FcεRI receptors and 
limits IgE-mediated allergic processes.
139
 It is important to remember that omalizumab binds any IgE 
molecule, irrespective of if it is a specific IgE-ab directed at the allergen of interest or not. When 
levels of total IgE-abs are high, the drug cannot bind enough IgE-abs to make treatment effective; 
thus, omalizumab is only recommended in patients with a total IgE of 30–1,500 kU/l.140 In patients 
with low IgE-ab levels the treatment is not approved, but if there is a clinically proven IgE-mediated 
allergy, treatment might still be effective if higher doses than recommended by the manufacturer are 
given (although still low doses).
141
  
When used together with immunotherapy, omalizumab combined with SCIT for pollen allergy was 
superior to placebo plus SCIT, both in terms of severity of side effects and in terms of outcome.
142
 In 
some cases, it is not even possible to start SCIT due to severe allergic reactions even at the lowest 
SCIT doses; here, omalizumab might facilitate the initiation of therapy.
143 
2.4.7 Omalizumab and food allergy 
The mechanisms by which omalizumab exerts its effect indicate that it should have an effect on IgE-
mediated diseases other than asthma. The positive effect on food allergies was observed by Rafi and 
colleagues, who followed 22 patients with both allergic asthma and food allergies: these patients 
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reported fewer events of food-induced symptoms (asthma, skin symptoms and anaphylaxis).
144
 Before 
omalizumab was approved, Leung et al. studied a similar anti-IgE drug, TNX 901, and showed that it 
induced a dose-dependent increased tolerance to peanuts with the highest effect at the highest drug 
dose (450 mg).
138
 Used as pre-treatment before initiation of OIT for food allergies, omalizumab has 
been shown to effectively increase the tolerated dose of the food.
23,39,40
 
2.4.8 OIT with adjuvant omalizumab 
In a pilot study on 11 milk-allergic children by Nadeau et al, from 2011,
40
 omalizumab was given for 
nine weeks followed by a rush-desensitization to cow’s milk. Ten patients took part in this rush-
desensitization starting at 0.1 mg and 9/10 patients reached the final 1,000 mg dose, although one was 
thereafter treated with epinephrine. Omalizumab was continued until week 16 and two months later, 
these nine patients tolerated OIT with 4–8 g of milk protein. Serious allergic reactions were seen after 
0.1 % of milk doses given. Schneider and colleagues in Boston treated 13 peanut-allergic children 
(median age 10 years) with omalizumab for 12 weeks,
145
 after which all patients passed a rush-
desensitization with doses ranging from 0.1 to 500 mg peanut flour. Doses were then further escalated 
up to 4 g of peanut flour, which was tolerated by 12/13 patients. At this time, the patients stopped 
omalizumab treatment but were kept on OIT and they all passed an 8 g peanut flour challenge. During 
treatment, two patients had severe allergic reactions, five had moderate reactions and six had mild or 
no reactions. 
In the last couple of years, two double-blind placebo-controlled studies of OIT (milk and peanut) plus 
omalizumab or OIT plus placebo have shed more light on the possible positive effects of adjunctive 
anti-IgE treatment in OIT. In the milk OIT study by Wood et al.,
36
 89 % of the omalizumab-treated 
subjects (n = 57, age 7–32 years) passed a milk challenge with a cumulative 10 g protein dose after 
two years of OIT, though this was not significantly higher than the 71.4 % seen in the OIT +placebo 
group (p = 0.18). Omalizumab was stopped at this time, but OIT was continued for eight more weeks. 
Thereafter, OIT was stopped and the patients were re-challenged after an additional eight weeks. At 
that time, 48 % in the former omalizumab group and 36 % in the former placebo group passed the 
same type of challenge (p = 0.42). As regards safety, the authors showed significant evidence of 
substantially lower frequencies of both mild symptoms (2 % vs. 16 %,) and symptoms requiring 
medical treatment (0 % vs. 3.8 %), for the omalizumab and placebo group, respectively, p ≤ 0.001. 
2.5 IMMUNOLOGIC EFFECTS IN ALLERGEN IMMUNOTHERAPY 
The first step towards allergen tolerance in AI is thought to be desensitization of basophils and mast 
cells. Antigen stimulation of these cells leads to a period of semi-refractory state where sensitivity to 
allergen stimulation is decreased. The antigen-induced release of tryptase and histamine from mast 
cells and basophils is also decreased during immunotherapy, decreasing the risk of reaching threshold 
levels for inducing allergic reactions.
146
 Plewako et al. showed that CD203 expression (marker of 
basophil activation) and basophil production of IL-4 and IL-13 are decreased in the first week of 
specific immunotherapy for cat allergy.
147
 Upregulation of the histamine H2 receptor (HR2) and 
concomitant suppression of FcεRI-induced basophil activation were demonstrated by Novak et al. in a 
study of patients undergoing bee venom immunotherapy.
148
 Meiler et al. made another HR2-related 
observation of bee venom-sensitized, but tolerant, bee-keepers. When stung again during a new 
season, the bee-keepers showed upregulation of the suppressing HR2 on allergen-specific Th2-cells.
149
 
Although the timing of the immunological events leading to tolerance is not known exactly and varies 
between patients, some patterns seem quite clear, Figure 4 and 5.
117
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Figure 4. Immunological changes induced by allergen immunotherapy and when these changes occur. The 
magnitudes of these changes are approximations. Modified from Akdis & Akdis.
117
 
2.5.1 Effects on antibodies  
Allergen-specific IgE-abs are the initiators of the IgE-mediated allergic reaction. However, there are 
individuals with high IgE-ab titers who tolerate the allergen of interest and among those who are 
allergic, severity grade correlates poorly with IgE-ab levels.
150
 Despite this, decreasing IgE-ab levels 
are often seen as allergies spontaneously resolve, as in children who outgrow cow’s milk allergy, 
although measurable quantities are usually still present.
151
 In AI, the typical pattern is an initial rise in 
IgE-ab titers, but IgE-abs to the allergen start to decline after years of treatment.
117
 In addition to the 
previously mentioned protective immunologic mechanisms (such as upregulation of HR2, IL-10, early 
desensitization of mast cells and basophils), there was a hypothesis of production of blocking 
antibodies postulated over 80 years ago.
152
 These blocking antibodies were later shown to be IgG-abs. 
The IgG-ab subtype IgG4 has been shown to play an important role in the development of tolerance, 
both in AI and when allergies are outgrown.
117,151
 It also plays a role in tolerant IgE-sensitized 
individuals; Santos et al. showed that sera from IgE-sensitized peanut-tolerant children that also 
contained peanut-specific IgG4-abs did not cause the dose-dependent basophil activation response in 
vitro that was observed when they used sera from peanut-allergic children. After depletion of IgG4 
from the peanut-sensitized but tolerant children, a partial basophil activation response was seen and 
taken as evidence for the protective properties of IgG4.
153
 So how do IgG4-abs stop or mitigate IgE-
mediated reactions? One theory is that IgG4 binds to FcγR on basophils, and while both inhibitory 
(FcγRIIB) and activating (FcγRIIA) receptors exist, the inhibitory signals are dominant and they in 
turn suppress the signals from IgE-FcεRI interaction.154 Burton et al. provided support for this theory 
in both mice and humans when they used blocking mAb for the inhibitory FcγRIIB, which resulted in 
increased IgE-mediated reactivity in vitro in egg-allergic mouse and peanut-allergic children going 
through immunotherapy.
155
 The other proposed mechanism is that IgG4 binds antigens in the tissues 
in competition with IgE. In a study of children recovering from milk allergy, IgG4 and IgE binding 
epitopes were shown to overlap. The IgE-antigen bonds were weaker after resolution of allergy 
compared with baseline values, patients who were still allergic had unaltered IgE-antigen binding.
151
 
Increased synthesis of IgA-ab in serum and secretory IgA-ab, has also been reported to be associated 
with successful immunotherapy and the main theory is that IgA works as a gatekeeper in the mucosa 
sIgE
Skin test
IgG4
Treg/Breg
Basophil/Mast
cell reactivity
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to prevent the allergen from entering the host.
156,157
 While increased levels of IgA might be a marker 
for tolerance development, causal mechanisms are far from proven. 
2.5.2 Effects on B and T cells 
In a study of IgE-sensitized but tolerant beekeepers, the balance of IFN-γ, IL-10 and IL-4 producing 
cells (Th1, Treg and Th2, respectively) was altered in favor of IL-10-producing Tregs after being 
stung.
149
 Bee venom allergen-specific B regulatory 1 cells are also increased during 
immunotherapy.
158
 aiTregs (allergen-induced) have been shown to be of importance when allergies 
are outgrown, as in milk-allergic children who outgrow their allergy.
159
 aiTregs have also been shown 
to increase during oral immunotherapy and an important modulator could be the Forkhead Box 
Protein 3 (FOXP3). Syed et al. have shown that DNA methylation of the FOXP3 gene is decreased 
(leading to increased FOXP3 synthesis) during the course of peanut OIT. They also showed that the 
demethylation was more pronounced in study patients who stayed tolerant to peanuts three months 
after stopping therapy compared with those who had lost their tolerance. Following the patients for 
another three months, they found that some additional patients lost their tolerance and this loss of 
tolerance was associated with an increased FOXP3-methylation. The authors could also show that 
expression of chemokine receptors such as CCR8 (chemokine c-motif receptor), for which FOXP3 is 
a transcription factor, increased on aiTregs and that aiTreg migration to intestinal epithelium started to 
increase after one year of OIT.
160
 
 
Figure 5. Chain of events induced by allergen immunotherapy. An initial de-sensitization occurs first, as basophils and 
mast cells get less sensitive to allergen stimulation after repeated exposure allowing for up-dosing. Induction of T-
regulatory cells and a subsequent altered balance of cytokine production affect antibody production in favor of 
protective IgG (IgG4) antibodies.61,117 
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3 AIMS 
The overall aim of this thesis was to improve the situation for children diagnosed with allergy to 
hazelnuts or peanuts. An improvement of the diagnostic accuracy of suspected hazelnut allergy would 
mean that fewer patients would receive a false positive diagnosis. For children with a severe peanut 
allergy, we hoped to increase tolerance to peanuts through the use of oral immunotherapy. 
Specific aims: 
I. To evaluate the diagnostic accuracy of basophil allergen threshold sensitivity (CD-sens) 
and component-resolved diagnostics in children with suspected hazelnut allergy. (Paper I) 
II. To assess whether an effective suppression of peanut allergy can be achieved by an 
individualized CD-sens monitored omalizumab treatment, where dose and duration are 
based on repeated CD-sens analyses. To try to find biomarkers or patient characteristics 
indicative of a need of an elevated omalizumab dose. (Paper II) 
III. To evaluate the safety and efficacy of peanut oral immunotherapy combined with 
individualized omalizumab adjunctive therapy in severely peanut-allergic adolescents. 
(Paper III)
 18 
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4 METHODS 
4.1 STUDY POPULATIONS 
4.1.1 The Hazelnut study (Paper 1)  
The study population for the hazelnut study consisted of 40 children aged 6–18 years who had been 
referred to Sachs’ Children and Youth Hospital to go through a hazelnut challenge. The study 
population consisted of patients with a suspected, but not confirmed, hazelnut allergy, in order to try 
to get as close to a “real life” clinical setting as possible. 
Referral notes were reviewed to assess conformity to the inclusion and exclusion criteria. Thereafter, 
the patients’ caregivers were contacted by phone by a research nurse and asked if they were interested 
in participating in the study. If the caregivers were interested in participating, written information was 
sent by mail.  
At the time of referral, all patients had to be IgE-sensitized to hazelnut, having either a positive SPT to 
hazelnut (> 3 mm) or positive IgE to hazelnut (> 0.35 kUA/l). Further, the patients were required to be 
on a hazelnut-elimination diet and patients with previous hazelnut-induced anaphylaxis were 
excluded. 
4.1.2 The FASTX study (Papers 2 and 3) 
The study population in the FASTX study (Food Allergen Suppression Therapy with Xolair®) 
consisted of adolescents who had a severe IgE-mediated peanut allergy. The patients were recruited 
from the outpatient allergy clinic at Sachs’ Children and Youth Hospital or referred by pediatric 
allergists in the Stockholm area. In addition, some patients/caregivers contacted the study team after 
hearing or reading about the study at clinicaltrials.gov, a website where clinical trials are listed. All 
patients had a history of dramatic allergic reactions to peanut, but those who had not had an evident 
peanut-induced anaphylactic reaction within the last five years went through an open peanut challenge 
prior to inclusion to confirm the severity of the peanut allergy. By only including adolescents with a 
severe allergy we obtained a homogenous study population. However, the main reason was to offer a 
potentially disease-modifying treatment to those who would benefit most. When choosing adolescents 
and not younger children we hoped to achieve: 1. Good ethics; patients participating of their own will. 
2. Less troublesome treatment; highly motivated patients who were not afraid of hospitals, injections 
and blood sampling, and. 3. Reliable reports of adverse events (with young children having a harder 
time reporting subjective symptoms).  
Since the FASTX study did not include a placebo arm, all patients were also required to have a 
concomitant allergy to either pollen or pets to serve as control. Additional inclusion criteria were 
positive IgE-test, SPT and CD-sens to peanut and control allergen. 
4.2 STUDY DESIGNS 
4.2.1 Hazelnut study 
We performed double-blind placebo-controlled food challenges (DBPCFC) to hazelnut and compared 
the outcome with the results from analyses of IgE-abs to hazelnut, the hazelnut components Cor a 1, 
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Cor a 8, Cor a 9 and Cor a 14 and CD-sens. Tryptase levels were measured before and after the 
challenge and also ~30 minutes after the onset of symptoms in case of a positive DBPCFC. 
4.2.2 FASTX study 
The FASTX study was an open one-armed exploratory phase-2 study of peanut oral immunotherapy 
combined with omalizumab. Laboratory data and patient history were collected at baseline and 
continuously throughout the study (Table 1). An open peanut challenge for those who had not 
experienced a peanut-induced anaphylaxis within the last five years was performed at baseline. 
 Baseline Start of OIT Maintenance Final visit 
Patient history X    
Peanut challenge X
a 
X  X
b 
IgE-abs to peanut and Ara h 1, 2, 3, 6, 8, 9 X   X 
IgG-abs and IgG4-abs to peanut, Ara h 2 and 
Ara h 6
c 
X X X X 
CD-sens to peanut X X X X 
CD-sens to control allergen X   X 
Skin prick test X   X
b 
Table 1. Major data collection time points in the FASTX study. aIf no peanut induced anaphylaxis < 5 years. bOnly in 
treatment success patients. cNot analyzed for drop-outs. 
The FASTX study was divided into two parts. In the first part, omalizumab was started at the dose 
recommended for asthma. This dose is based on a combination of body weight and total serum IgE. If 
CD-sens to peanut was negative after eight weeks of treatment (or only reactive at the highest allergen 
concentration), an open peanut challenge was performed which marked the end of the first part of the 
study. If a CD-sens value could be calculated, omalizumab was given for another eight weeks with a 
~50 % increased dose. This procedure was repeated until CD-sens was suppressed (but not exceeding 
the maximum recommended dose of omalizumab); thereafter, the open peanut challenge ensued.  
 
Figure 6. Study design FASTX 1st part. 
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Next, the second part commenced with peanut oral immunotherapy at a dose of 280 mg of peanut 
protein, which was increased biweekly until reaching the 2,800 mg maintenance dose. After eight 
weeks of maintenance doses, we decreased the omalizumab dose (~50 %) if the patient was free of 
symptoms and CD-sens did not indicate an increased sensitivity to peanuts. This procedure was 
repeated every eighth week until OIT was tolerated at the lowest omalizumab dose (75 mg every 
fourth week). At that time, omalizumab was discontinued while OIT continued for 12 more weeks, 
followed by an open peanut challenge (Figure 7). 
 
 
 
 
 
 
 
 
 
 
Figure 7 Study design FASTX 2nd part. 
 
4.3 PROCEDURES 
4.3.1 Food challenges 
In the hazelnut study, double-blind placebo-controlled food challenges (DBPCFC) were used to 
minimize psychological influence. The challenge medium consisted of chocolate balls containing 11 
% raw hazelnuts (omitted in the placebo medium) and was prepared by a dietician using a slightly 
modified, previously validated, recipe for blind peanut challenges.
161
 The challenge consisted of 5 
doses of hazelnut: 1 mg, 10 mg, 100 mg, 1 g and 5 g given at 30-minute intervals. The challenge was 
stopped and ruled positive if the patient had objective symptoms of any severity. Symptom severity 
was scored as described by Astier.
162
  
In FASTX, the challenges were not done to confirm a diagnosis of peanut allergy and therefore we did 
not find it necessary to perform blinded or placebo-controlled challenges. The purpose of the first 
challenge was to confirm the severity of the allergy by inducing anaphylaxis. Doses were increased 
every 30 minutes (0.1, 1 mg, 10 mg, 100 mg, 1 g, and 10 g). The challenge was not stopped in case of, 
e.g., itching, hives or abdominal pain, but when we were convinced that an anaphylaxis was on the 
verge of breaking out, the challenge was stopped. Also, doses or dosing intervals could be adjusted at 
the discretion of the physician. Contrary to common practice, we did not give prompt medication in 
Peanut OIT: starting dose 280 mg peanut protein, n = 23 
Dose increments every 14
th
 day if tolerating previous dose:  
560, 1,120, 2,240 and maintenance dose 2,800 mg  
CD-sens analysis 8 weeks into maintenance phase  
and every 8
th
 week thereafter 
CD-sens not increased 
Patient ok 
 
 
 
CD-sens increased 
Allergic symptoms 
 
 
Omalizumab 
dose maintained 
or increased 
 
 
Omalizumab 
reduced by 50 % 
 
 Omalizumab stopped after tolerating 
OIT with 75 mg omalizumab 
 
pOIT 12 more weeks 
Open peanut challenge 
n = 11 
 
Drop-out 
n = 6 
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the absence of anaphylaxis, but patients were in these cases under very close supervision with 
emergency treatment drugs readily available.  
In the 2
nd
 challenge (just before starting OIT) we aimed to assess how much peanuts the subjects 
tolerated after the optimized omalizumab dose and confirm that the subjects could tolerate at least the 
280 mg peanut protein OIT starting dose. This challenge followed the same dosing intervals as 
challenge 1. The 3
rd
 challenge, at the final visit, was done to objectively assess that each patient 
tolerated her/his maintenance OIT dose, post-omalizumab discontinuation, and was performed as a 
serving of the patient’s maintenance pOIT dose.  
4.3.2 CD-sens 
In the hazelnut study, CD-sens to hazelnut in whole blood was analyzed from blood samples drawn 
just prior to the first of the two visits for DBPCFC. In FASTX, both whole blood and washed sample 
CD-sens to peanut were analyzed continuously (8-week intervals) throughout the study, whereas CD-
sens to control allergen was analyzed at baseline and at the final visit.  
Peripheral blood samples were collected in sterile sodium-heparin collecting tubes. The CD-sens 
analyses were performed within 24 h (samples stored at +4˚ C pending analysis).163 The plasma-
depleted washed samples were prepared by suspending blood in PBS followed by centrifugation and 
aspiration of supernatant (twice), followed by resuspension of pellets in RPMI (Rosewell Park 
Memorial Institute 1640 cell culture medium). Next, both washed and unwashed samples were 
portioned into tubes and allergen was added. In-house peanut and hazelnut extracts were used and 
diluted into 8 different concentrations (final peanut protein concentration: 0.83–2,500 ng/ml), (final 
hazelnut protein concentration: 2-200,000 ng/ml). For control allergens we used commercial extracts 
(ALK, Copenhagen, Denmark) (final concentrations 5–5,000 SQU/ml). For positive and negative 
control, we added 25 µl of anti-FcεRI-abs and 100 µl of RPMI, respectively. To be able to identify the 
basophils and activated basophils, anti-CD63 and anti-CD203c (18 µl) were added to each tube. After 
20 minutes incubation, lysing buffer was added (followed by centrifugation and supernatant 
aspiration) to remove erythrocytes from the samples. 
The samples were then analyzed using flow cytometry, where basophils were identified as cells within 
the 203c+/SSC
low
 (low side scatter) gate and activated basophils as the CD63+ cells within the 
203c+/SSC
low 
gate. 
4.3.3 IgE and IgG/G4 analysis 
Hazelnut study. Samples acquired before the first challenge were stored in -20˚C. At the completion 
of the study, IgE-abs to hazelnut, Cor a 1, Cor a 8, Cor a 9 and Cor a 14 were analyzed with 
ImmunoCAP® (Thermo Fisher Scientific, Uppsala, Sweden) by a certified biomedical scientist, in 
accordance with the instructions from the manufacturer. 
FASTX. Blood samples for analyses of IgE-abs to peanut, control allergen and Ara h 1, Ara h 2, Ara 
h 3, Ara h 8 and Ara h 9 were immediately sent to where samples were analyzed at Karolinska 
University Hospital Laboratory with ImmunoCAP® (Thermo Fisher Scientific, Uppsala, Sweden), in 
accordance with the instructions from the manufacturer. We also chose to include analysis of IgE-abs 
to the peanut component Ara h 6 (baseline and final visit) which was not a part of the initial study 
protocol. IgE-abs to Ara h 6 were analyzed with ImmunoCAP® (Thermo Fisher Scientific, Uppsala, 
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Sweden) by a certified biomedical scientist, in accordance with the instructions from the 
manufacturer. 
IgG-abs and IgG4-abs to peanut, Ara h 2, Ara h 6 and control allergen were analyzed at four time 
points: baseline, start of OIT, eight weeks into maintenance phase and at final visit. Serum was 
collected at these time points and stored at -20˚C. All analyses were carried out at a single time point 
by a certified biomedical scientist using the ImmunoCAP® method.  
4.3.4 Skin prick test and conjunctival provocation (FASTX study) 
SPT and conjunctival provocations were performed by a trained nurse or the author (after receiving 
training from a trained nurse). For SPT, we used commercial Soluprick® extracts, histamine and 
diluent were used as positive/negative controls (ALK, Copenhagen, Denmark). Skin prick tests 
(peanut and control allergen) were performed on all patients at baseline, but only on treatment 
successes at the final visit since the remaining patients were still being treated with omalizumab, 
which affects SPT.
164
  
Conjunctival provocations (control allergen) were performed at baseline by placing one drop of 
100,000 SQU/ml Aquagen (ALK, Denmark) allergen extract in one eye and saline in the other eye as 
negative control. Symptoms were graded by the physician (0–3) and by the patient on the 0–10 VAS 
(visual analogous scale). We planned to perform the test at the final visit as well. However, due to 
unavailability of extracts at the time of final visits, the test could not be performed. 
4.4 DATA COLLECTION AND STATISTICS 
4.4.1 Data collection 
Hazelnut study. Data were continuously collected in electronic medical charts and paper forms by the 
responsible physician and thereafter entered into the statistical software. CD-sens and IgE-abs were 
analyzed by staff who were blinded to all patient data, including outcome of the DBPCFC. At the 
DBPCFC, all involved staff and the patients were unaware of which of the two challenges was with 
hazelnuts. However, the physician supervising the challenges did have access to previous SPT and/or 
IgE-ab analyses. 
FASTX. We set out to collect all data in a database created for this purpose. However, we soon 
realized that we had to use the electronic medical charts for collection of data, especially to be able to 
describe symptoms at food challenges and adverse events during OIT in detail. Patients, physicians 
and nurses were not blinded to any patient data, while laboratory staff were blinded. 
Adverse events, allergic reactions, and other potential adverse events such as illnesses that occurred 
throughout the study period were reported by the patients or their parents. They reported symptoms by 
phone or at visits at the clinic. Medical records were reviewed when patients visited the emergency 
department or were hospitalized. We recorded the frequency of allergic symptoms during pOIT, 
however, for the two mildest symptoms, oral pruritus and mild abdominal pain, we did not register the 
exact number of events. All reactions were retrospectively reviewed to assess severity. The allergic 
reactions were classified as systemic reactions if there was involvement of at least two organ systems. 
A systemic reaction not fulfilling the World Allergy Organisation (WAO) criteria for anaphylaxis
165
 
was classified as mild while reactions fulfilling the WAO criteria for anaphylaxis were further 
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subdivided by the anaphylaxis severity grade as described by Muraro et al. in EAACI guidelines,
166
 
into moderate, anaphylaxis grade 1–2, and severe, anaphylaxis grade 3. 
4.4.2 Statistical analysis 
In the hazelnut study, GraphPad Prism 5.01 (GraphPad Software Inc. Ca, USA) was used for all 
statistical analyses and in FASTX we used STATA 14.0 (Stata Corp, TX, USA). For all papers 
included in this thesis, p values < 0.05 were considered significant (no adjustments for multiple 
analyses were made). 
In paper 1, the hazelnut study, we compared IgE-ab levels and CD-sens to hazelnut in relation to 
outcome of DBPCFC. Data were reported as medians and 25
th
/75
th
 percentiles and the Wilcoxon rank-
sum test was used when comparing groups as data were not normally distributed. ROC curves 
(receiver operating characteristic curves) where constructed to find the cut-off levels for IgE-abs/CD-
sens with the highest possible sensitivity and specificity. 
In the first FASTX study (paper 2) we reported laboratory data and other continuous variables as 
medians and 25
th
/75
th
 percentiles. Binomial variables were presented as percentages. For statistical 
comparison of the two groups (normal dose (omalizumab) and elevated dose) we used Fisher’s exact 
test for binomial variables and Wilcoxon rank-sum test for continuous variables (in the published 
version of this paper we wrongly state that Fisher’s test was used for both). ROC calculations were 
also performed on baseline predictors of outcome. 
In the 2
nd
 FASTX study (Paper 3) we looked for changes over time in IgE/IgG-ab levels, CD-sens, and 
SPT. In these serial observations we used the non-parametric Page’s test for trends and the sign-rank 
test for comparison of two time points. Descriptive statistics were carried out using Fisher’s exact test, 
Wilcoxon rank-sum test (comparing two groups) and Kruskal-Wallis test (comparing 3 groups at 
once).  
4.5 ETHICS AND REGISTRATION 
All studies within this thesis were approved by the Stockholm Ethics Committee (Hazelnut study; 
2012/990-31/3, FASTX; 2013/827-31/3 and two amendments that were approved 20 November 2014 
and 13 December 2015, respectively). The FASTX study was also approved by the Swedish Drug 
Agency (5.1-2013-46183). All caregivers of the patients in these studies (or the patient if > 18 years of 
age) provided written informed consent. The FASTX study was registered at ClinicalTrials.gov; 
NCT02402231 and EudraCT; 2012-005625-78.
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5 RESULTS 
Results are in general reported as: median (25
th
-75
th
 percentile) and if not so it is stated.  
5.1 FOOD CHALLENGES (PAPERS 1-3) 
In the hazelnut study, only 8/40 (20 %) of the patients, who all avoided hazelnuts due to suspected 
hazelnut allergy (based on patient history and previous diagnostic work-up), reacted with objective 
symptoms at food challenge. This means that 80 % of the patients had either received an incorrect 
diagnosis or had outgrown their allergy. There were no observed reactions in the 40 placebo 
challenges. Another interesting finding was that in ¼ of the positive challenges (5 % of all DBPCFCs) 
the patient was admitted to the pediatric ward for continued observation due to severe symptoms.  
In the FASTX study, we performed the 1
st
 peanut challenge to confirm the severity of each subject’s 
peanut allergy. This challenge was performed on 13/23 patients (one patient had gone through a 
DBPCFC within another study). The median dose ingested at this challenge was 91 mg peanut 
protein, but symptoms usually presented at lower doses (dose escalation was not stopped for 
subjective symptoms or mild objective symptoms). Of the challenged patients; 9/14 received ≥ 1 dose 
of adrenaline, four were hospitalized and two of them had bi-phasic reactions with recurring 
respiratory symptoms. All 23 patients participated in the 2
nd
 peanut challenge that took place once we 
observed omalizumab-induced suppression of CD-sens to peanut. Even if the patient tolerated the 
maximum 2,800 mg peanut protein dose, the challenge was stopped at this dose. Table 2 summarizes 
objective symptoms observed in these challenges and also at the final peanut challenge which was 
performed 12 weeks after stopping omalizumab (while still being on peanut OIT). 
 Before omalizumab  
(n = 14) 
With omalizumab  
(n = 23) 
After omalizumab and OIT  
(n = 11) 
Objective symptoms 
Vomiting 7 (50 %) 0  0 
Urticaria  6 (43 %) 1 (4 %) 0 
Conjunctivitis 6 (43 %) 4 (17 %) 0 
Asthma 4 (29 %) 0  0 
Rhinitis 4 (29 %) 3 (13 %) 0 
Cough 3 (21 %) 0  0 
Erythrodermia 3 (21 %) 1 (4 %) 0 
Muffled voice 3 (21 %) 0 0 
De-saturation (< 90 %) 1 (7 %) 0  0 
Stridorous breathing 1 (7 %) 0  0 
Adrenaline ≥ 1 dose 9 (64 %) 0  0 
Adrenaline ≥ 2 doses 4 (29 %) 0  0 
Adrenaline 3 doses 1 (7 %) 0  0 
Peanut protein dose in mg    
Median (min-max) 91 mg (28–840) 2,800 (840–2,800) 2,800 (700–2,800) 
Table 2. Objective symptoms, adrenaline treatment and ingested peanut dose at peanut challenges 1, 2 and 3 (1; at 
baseline in those subjects without history of anaphylaxis within the last five years, 2; while on omalizumab after CD-
sens to peanut was suppressed, 3; while on OIT after discontinuing omalizumab). 
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5.2 DIAGNOSTIC MARKERS FOR HAZELNUT ALLERGY (PAPER 1) 
5.2.1 IgE-abs to hazelnut and hazelnut components 
The study population had high titers of total serum IgE with a median of 423 kU/l (230–996). 
Sensitization to hazelnut was present in 39/40 patients; median 9.75 kUA/l (3.73–36.2) and did not 
differ significantly in those with confirmed hazelnut allergy, median 11.4 (6.51–79.8), and in those 
tolerant to hazelnuts, median 9.2 (3.03–34.9) (P = 0.34). Half of the patients in both groups had a 
hazelnut IgE < 10 kUA/l. Tolerant patients had higher IgE-ab levels to Cor a 1 (cross-reactive with 
birch) and birch; three of eight hazelnut-allergic patients had no IgE-abs to birch at all (median 0.82 
kUA/l (0–7.56)), while among the tolerant patients 31/32 were birch-sensitized (median 12.6 kUA/l 
(3.12–63.8)) (P = 0.013).  
All hazelnut-allergic patients were sensitized to both Cor a 9 and Cor a 14. Cor a 14 IgE-abs differed 
most between allergic and tolerant patients; median 5.6 kUA/l (0.9–78.7) for allergic, median 0.04 
kUA/l (0–13.9) for tolerant (P < 0.001). Median IgE-ab levels to Cor a 9 were 4.5 kUA/l (0.7–97) and 
0.1 kUA/l (0–36.2) in hazelnut-allergic and in tolerant patients respectively (P < 0.01). 
 
 
Figure 8. IgE-abs to hazelnut and hazelnut components. ○=hazelnut-allergic, □= hazelnut-tolerant. 
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ROC curves were generated and for Cor a 14 a sensitivity and specificity of 100 % and 94 % 
respectively at a cut-off of 0.64 kUA/l was reached, while the corresponding figures for Cor a 9 was 
100 % sensitivity with 72 % specificity (cut-off 0.65 kUA/l). The 95 % confidence intervals for the 
area under the curve were overlapping for the Cor a 14 and Cor a 9 ROC curves (Figure 9). 
 
Figure 9. ROC curves for IgE-abs to Cor a 14 and Cor a 9. 
5.2.2 CD-sens 
CD-sens to hazelnut had a sensitivity of 100 %, since all patients with a positive DBPCFC were 
positive in CD-sens to hazelnut. While most (24/32) tolerant patients had a positive CD-sens, their 
values were, with one exception, much lower. Median CD-sens in hazelnut-allergic patients was 8.9 
(5.2–41), while tolerant patients had a median of 0.05 (0.007–0.11), making for a highly significant 
difference, P < 0.0001. At a ROC-generated cut-off of CD-sens ≥ 1.7, a sensitivity of 100 % and 
specificity of 97 % was reached (Figure 10). 
   
Figure 10. a. CD-sens to hazelnut among hazelnut-allergic patients= ○ and patients tolerant to hazelnut at 
DBPCFC=□. b. ROC curve for CD-sens to hazelnut in relation to outcome of DBPCFC. 
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5.3 FASTX (PAPERS 2 AND 3) 
Forty-one patients were assessed for eligibility and 23 matched the inclusion criteria. The main reason 
for being excluded was too high total serum IgE (in 10/18 non-included subjects). However, there 
were no limitations in IgE-abs to peanut, possibly resulting in patients with high ratios of allergen-
specific IgE-abs to peanut (and peanut components) in relation to total IgE. Six patients were not 
included since they were negative to the control allergen in CD-sens.  
Table 3 reports patient characteristics of the whole study population in papers II and III (patient 
characteristics in paper II are reported in relation to if the subject received an increased omalizumab 
dose or not, while in paper III they are reported in relation to outcome of peanut OIT). 
 
Patient characteristics n (%) 
Gender, female  16 (70) 
Conjunctivitis 21 (91) 
Asthma 20 (87) 
Rhinitis 20 (87) 
Eczema 6 (26) 
Other food allergy 14 (61) 
Allergic to tree/grass pollen 20 (87) 
Allergic to pets 18 (78) 
> 2 atopic manifestations 15 (65) 
 Median (25
th–
75
th
 percentile) 
Skin prick test peanut, mm 10 (9–14) 
Total serum IgE, kU/l 470 (230–680) 
Peanut, kUA/l 86 (48–220) 
Ara h 2, kUA/l 58 (26–78) 
Ara h 6, kUA/l 49 (26–66) 
Ara h 8, kUA/l 2.3 (0.61–6.6) 
Ara h 2/total IgE  14.4 % (10.6–20) 
CD-sens peanut 0.8 (0.4–1.9) 
Omalizumab start dose (mg per 4 weeks) 600 (150–1,050) 
Age, years (min-max) 17 (12–19) 
Table 3. Patient characteristics of the study population in papers II and III. 
5.3.1 Dosage of omalizumab  
After eight weeks of treatment with omalizumab (at doses recommended for asthma) CD-
sens was suppressed in 8/23 patients (CD-sens was completely negative or showed a small 
reaction at the highest allergen concentration only). Among twelve of the remaining 15 
patients, basophils were suppressed after eight more weeks of treatment with omalizumab 
with an increased dose. In another patient, basophil suppression was reached at week 24, 
while one patient (who already had been on the maximum allowed dose since week 8) was 
still barely positive in CD-sens but was allowed to move on to the peanut challenge. The last 
patient needed 32 weeks of omalizumab treatment, with a final dose 400 % higher than the 
starting dose in order to suppress CD-sens to peanut (Figure 11). 
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Figure 11. Initial and final dose of omalizumab. Each line represents a patient; when patients have identical starting 
and final doses the lines are slightly offset from the actual values they represent; e.g., when the graph shows value of 
580, the actual value is 600.  
5.3.2 Who needs an increased omalizumab dose? 
In terms of medical history of atopic diseases and age, there were neither any significant differences 
nor any interesting trends in relation to a need for an increased omalizumab dose. Patients who needed 
an increased omalizumab dose had higher CD-sens to peanut, median 1.5 (0.61–2.7), compared with 
those who did not increase their dose, 0.32 (0.28–0.55). Total serum IgE was markedly higher (in 
median 660 kU/l) among those whose basophil response to peanut was suppressed after eight weeks 
of omalizumab (at a normal asthma dose) compared with 260 kU/l (P < 0.01) among the subjects who 
needed an elevated dose. Also the IgE-ab levels to peanut and peanut components were lower (not 
significantly) among those who needed an increased omalizumab dose. The ratio of Ara h 2 IgE/Total 
IgE was in median 17.1 % (5.8–50 %) in the group who needed an increased omalizumab dose; 
significantly higher than the median ratio of 10.9 % (5.2–15.4) in the normal omalizumab group (P = 
0.02).  
5.4 PEANUT ORAL IMMUNOTHERAPY (POIT) 
The immunotherapy in FASTX consists of three phases. The first two were the up-dosing phase and 
the maintenance phase (during this phase omalizumab treatment was gradually phased out) (reported 
in paper III). In the third phase, which is still ongoing, OIT is given for an additional three years 
(without omalizumab). During up-dosing and maintenance, approximately 16,000 pOIT doses were 
administered. 
Up-dosing phase: After the 2
nd
 peanut challenge (where all patients ingested > 3 g of peanuts), pOIT 
was initiated at home the following day with 1 g of peanut ~280 mg peanut protein. During up-dosing 
at home, two patients had moderate adverse events while on this first dose step (1 g); both occurring 
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after physical exercise. These were the only systemic reactions observed during up-dosing (roughly 
1,860 pOIT doses were administered). Most patients experienced mild oral itching or mild abdominal 
pain during up-dosing, depending on frequency and intensity this affected how fast the up-dosing 
could be performed. The maintenance dose of 10 g of peanuts was reached in a median of ten weeks 
(8–13 weeks). However, it turned out that the subjects who later successfully completed the study 
reached the maintenance dose faster, in eight weeks (median), compared with those who could not 
successfully discontinue omalizumab, needing 14 weeks to reach maintenance dose. Patients who later 
dropped out of the study were in between (11.5 weeks). No patients dropped out during up-dosing. 
Maintenance phase: Dose reduction of omalizumab was considered every 8
th
 week. There was a 
wide variance of the rate that omalizumab could be decreased and it became apparent after two years 
that some patients might not be able to discontinue omalizumab in a near future. Therefore we 
decided, at an investigator’s meeting in March 2016, that patients still treated with omalizumab in 
September 2017 should be considered treatment failures. Treatment successes received pOIT for a 
median time of 83 weeks (min-max 48–156), while the treatment failures (still on omalizumab) had 
been on pOIT for 139 weeks (115–166). Among the drop-outs, the median time of pOIT was 72 
weeks (min-max 38–120). 
The primary end-point, passing the 10 g peanut challenge after tolerating pOIT with 10 g of peanuts 
for 12 weeks after the omalizumab treatment was stopped, was met by 9/23 (39 %) subjects. Two 
more patients also completed the study, but with a reduced pOIT dose (~2.4 and 4 grams), as they had 
developed a profound abomination for the taste of peanuts. Study completion with any pOIT dose was 
met by 11/23 (48 %) of the subjects. When excluding drop-outs (per-protocol analysis), 11/17 (65 %) 
successfully completed the study.  
In all but two patients either adverse events or an increasing CD-sens value made us postpone the 
down-escalation of one or more omalizumab doses. 
5.4.1 Adverse events 
There were 43 systemic reactions attributed to pOIT during the FASTX study. One was classified as 
severe, 22 as moderate and 20 as mild. A vast majority (19/22) of moderate systemic reactions were 
graded as moderate based on reports of subjective breathing difficulties in combination with 
symptoms from the skin or mucosal tissues. The frequency of systemic reactions was one per 374 
pOIT doses ingested (0.3 %), but the cumulative incidence was 70 % (16/23) and 43 % were treated 
with adrenaline at least once. Patients who dropped out (n = 6) did not have more frequent allergic 
reactions than the other patients (n = 17) and in general had fewer episodes with allergic symptoms 
than treatment failures. One patient developed eosinophilic esophagitis. Table 4 shows detailed 
information of allergic AEs among treatment successes and treatment failures.  
The study design does not allow us to make causal inference as to whether omalizumab decreases the 
risk of AEs or not, but two interesting observations can be reported: Of the 43 systemic reactions, only 
four occurred while the subject was on full dose omalizumab, and among treatment failures, 22/27 
systemic reactions occurred when the omalizumab dose was reduced to ≤ 25 % of the original dose. 
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 Total (n = 17) Treatment success (n = 11) Treatment failure (n = 6) 
Total peanut doses 12,915 6,978 5,937 
Peanut doses per 
child, mean 
(range) 
760 (336–1,163) 634 (336–1,093) 990 (804–1,163) 
Patients 
with eventᵇ 
n (%) 
Mean 
(range) for 
patients 
with eventᵇ 
Doses 
with 
eventᵇ 
n (%) 
Patients 
with 
eventᵇ 
n (%) 
Mean 
(range) for 
patients 
with eventᵇ 
Doses 
with 
eventᵇ 
n (%) 
Patients 
with 
eventᵇ 
n (%) 
Mean 
(range) for 
patients 
with eventᵇ 
Doses 
with 
eventᵇ 
n (%) 
SYMPTOMS          
Skin          
Urticaria 7(41.2) 1.9(1–3) 13(0.1) 3(27.3) 1.3(1–2) 4(0.1) 4(66.7) 2.3(1–3) 9(0.2) 
Erythema-flush 1(5.9) 6.0(6) 6(0.0) 0 - 0(0) 1(16.7) 6.0(6) 6(0.1) 
Angioedema 2(11.8) 2.0(1–3) 4(0.0) 1(9.1) 1.0(1) 1(0.0) 1(16.7) 3.0(3) 3(0.1) 
Pruritus 9(52.9) 2.8(1–8) 25(0.2) 4(36.4) 2.0(1–3) 8(0.1) 5(83.3) 3.4(1–8) 17(0.3) 
Gastrointestinal          
Vomiting 2(11.8) 1.5(1–2) 3(0.0) 1(9.1) 1.0(1) 1(0.0) 1(16.7) 2.0(2) 2(0.0) 
Severe abd. pain 5(29.4) 1.2(1–2) 6(0.0) 3(27.3) 1.3(1–2) 4(0.1) 2(33.3) 1.0(1) 2(0.0) 
Respiratory          
Conjunctivitis 2(11.8) 1.0(1) 2(0.0) 1(9.1) 1.0(1) 1(0.0) 1(16.7) 1.0(1) 1(0.0) 
Rhinitis 4(23.5) 6.3(1–21) 25(0.2) 1(9.1) 1.0(1) 1(0.0) 3(50.0) 8.0(1–21) 24(0.4) 
Cough 1(5.9) 1.0(1) 1(0.0) 0 . . 1(16.7) 1.0(1) 1(0.0) 
Subj. throat tight. 8(47.1) 1.8(1–4) 14(0.1) 3(27.3) 1.3(1–2) 4(0.1) 5(83.3) 2.0(1–4) 10(0.2) 
Chest tightness 2(11.8) 1(1) 2(0.0) 0 - 0(0*) 2(33.3) 1.0(1) 2(0.0*) 
Subj. breath. diffic. 9(52.9) 2.8(1–8) 25(0.2) 4(36.4) 1.4(1–4) 8(0.1) 5(83.3) 3.4(1–8) 17(0.3) 
Wheeze 0(0) - 0(0) 0 - 0(0) 0 - 0(0) 
De-sat < 92 %) 1(5.9) 1.0(1) 1(0.0) 1(9.1) 1.0(1) 1(0.0) 0 - 0(0) 
Neuro-cardiovasc.          
Chest pain 2(11.8) 2.0(2) 4(0.0) 1(9.1) 2.0(2) 2(0.0) 1(16.7) 2.0(2) 2(0.0) 
Dizziness 2(11.8) 1.0(1) 2(0.0) 1(9.1) 1.0(1) 1(0.0) 1(16.7) 1.0(1) 1(0.0) 
Syncope 1(5.9) 1.0(1) 1(0.0) 1(9.1) 1.0(1) 1(0.0) 0 - 0(0) 
Hypotension 0 - 0(0) 0 - 0(0) 0 - 0(0) 
SYSTEMIC 
REACTIONSᵃ 
12(70.6) 3.1(1–14) 37(0.3) 6(54.6) 1.7(1–3) 10(0.1) 6(100) 4.5(1–14) 27(0.5) 
Mildᶜ 8(47.1) 2.1(1–7) 19(0.1) 5(45.5) 1.2(1–2) 6(0.1) 3(50) 4.3(2–7) 13(0.2) 
Moderate ᵈ  7(41.2) 2.4(1–7) 17(0.1) 2(18.2*) 1.5(1–2) 3(0.0*) 5(83.3*) 2.8(1–7) 14(0.2*) 
Severe ᵉ 1(5.9) 1(1) 1(0.0) 1(9.1) 1(1) 1(0.0) 0 - 0(0) 
DRUGS adm.           
i.m. adrenaline 8(47.1) 1.9(1–4) 15(0.1) 3(27.3) 1.7(1–3) 5(0.1*) 5(83.3) 2(1–4) 10(0.2*) 
  At home 7(41.2) 1.9(1–3) 13(0.1) 2(18.2*) 2(1–3) 4(0.1*) 5(83.3*) 1.8(1–3) 9(0.2*) 
  In ambul/hospital 2(11.8) 1(1) 2(0.0) 1(9.1) 1(1) 1(0.0) 1(16.7) 1(1) 1(0.0) 
  Repeated doses 1(5.9) 1(1) 1(0.0) 0 - - 1(16.7) 1(1) 1(0.0) 
Inhaled b-2 agonist 7(41.2) 1.7(1–3) 12(0.1) 3(27.3) 1.7(1–3) 5(0.1) 4(66.7) 1.8(1–2) 7(0.1) 
  At home 7(41.2) 1.7(1–3) 12(0.1) 3(27.3) 1.7(1–3) 5(0.1) 4(66.7) 1.8(1–2) 7(0.1) 
  In ambul/hospital 1(5.9) 1(1) 1(0.0) 1(9.1) 1(1) 1(0.0) 0 - 0(0) 
Intravenous fluid 2(11.8) 1(1) 2(0.0) 2(18.2) 1(1) 2(0.0) 0 - 0(0) 
ED visit 7(41.2) 1.9(1–3) 13(0.1) 3(27.3) 1.7(1–2) 5(0.1) 4(66.7) 2.0(1–3) 8(0.1) 
Hospital admission 2(11.8) 1(1) 2(0.0) 0 - 0(0*) 2(33.3) 1(1) 2(0.0*) 
Table 4. Peanut doses, allergic symptoms, administered medical therapy and ED-visits in relation to outcome. 
ᵃSystemic reaction = dose-related allergic reaction with involvement of ≥ 2 organ systems, ᵇEvent = peanut dose 
related symptom, systemic reactionᵃ, administered therapy or ED-visit, ᶜMild systemic reaction = systemic reaction 
but not anaphylaxis, ᵈ Moderate systemic reaction = anaphylaxis grade 1–2, ᵉ Severe systemic reaction = anaphylaxis 
grade 3, * TF vs. TS: p value < 0.05. Abbreviations: abd. =abdominal, de-sat=desaturation, i.m.=intramuscular, Subj. 
breath. diffic.= subjective breathing difficulties 
5.4.2 Drop-outs 
Six patients dropped out of the study. These six patients did not differ from the other study 
participants in terms of baseline levels of IgE-abs, CD-sens or patient history, neither did they 
experience worse or more frequent allergic reactions. One of the patients had almost completed the 
study (omalizumab had been stopped) when a gastroscopy performed as part of the diagnostic work-
up of long-lasting symptoms (chronic cough and difficulties swallowing certain foods) revealed that 
he suffered from eosinophilic esophagitis. He stopped pOIT and his symptoms resolved completely. 
The other five patients who dropped out did so for personal reasons, fear of having allergic reactions, 
lack of motivation and moving/travelling, they also highly disliked the taste of peanuts which 
contributed to their decision.  
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5.5 IMMUNOLOGY 
5.5.1 Predictors of outcome 
Just as in the first FASTX paper (paper II), where a high CD-sens indicated a need for a higher 
omalizumab dose, pOIT treatment failures had higher CD-sens to peanut at baseline with a median of 
6.7 (1.5–9.5) compared with the treatment successes whose median was 0.52 (0.29–1.5) (P = 0.021). 
IgE-abs to peanut and peanut components Ara h 1, 2 and 3 were also significantly higher among those 
failing the pOIT protocol, e.g., Ara h 2: 72 kUA/L (58–185) vs. 30 kUA/L (24–66) (P = 0.034). 
5.5.2 Immunological changes 
IgE-ab levels to peanut, peanut components and control allergen at the end of the study were not 
significantly different compared with the baseline levels. However, the SPT reaction to peanut 
decreased significantly in the successfully treated patients from a baseline median of 12 mm to 7 mm 
at final visit (P < 0.01) while SPT to the control allergen showed a slight, non-significant decline from 
7 mm to 5 mm (P = 0.1).  
IgG-ab and IgG4-ab production to peanut (and peanut components) was induced by pOIT but not by 
omalizumab. From baseline to the start of pOIT IgG/G4-titers remained literally constant, but 
increased markedly after the up-dosing phase in all patients. Also, IgG/G4 levels to control allergens 
remained very stable throughout both omalizumab and pOIT.  
During maintenance phase, however, the successfully treated patients had a significantly higher 
increase in IgG4 to peanut, Ara h 2 and Ara h 6. Final levels of IgG4-abs to Ara h 2 among 
adolescents with treatment success were 6 times higher than at start of the maintenance phase (P < 
0.01), whereas the corresponding increase for treatment failures was only 1.3-fold (P = 0.35). 
The allergen-binding activity (ABA) increased significantly from a baseline 3.8 (2.2–5.9) to a final 
visit value of 49 (9–89) (P < 0.01) among the successfully treated subjects. We also observed a 
positive correlation between ABA and IgG4 to peanut (rho = 0.67, P = 0.0499), to Ara h 2 (rho = 0.70, 
P = 0.036) and to Ara h 6 IgE-abs (rho = 0.70, P = 0.036) at the end of the study. In these analyses of 
ABA and correlations between ABA-IgG4 we had to exclude two patients who had turned into “non-
responders” in CD-sens (non-reactive in CD-sens to peanut, control allergen and positive control 
(FcεRI-stimulation). 
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Figure 12. IgG4-  
Control allergen. Error bars are presented as median (inter quartile range). A statistical significance was considered 
at a p value of < 0.05. 
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5.6 UNPUBLISHED DATA 
5.6.1 Subgroup analysis of CD-sens in hazelnut diagnostics study 
There were 23 patients in the hazelnut study who had an IgE-ab level of > 0.35 kUA/l to Cor a 9 or 
Cor a 14 (15 tolerant and all 8 allergic patients). In a kind of sensitivity analysis, the ability of CD-
sens to discriminate between allergy and tolerance was assessed when patients below different cut-off 
points for Cor a 9/Cor a 14 were excluded from analyses (Table 5).  
 Tolerant Allergic P 
All patients n = 32 n = 8  
CD-sens, median (min-max)  0.05 (0–34.7) 8.9 (3.1–281) < 0.0001 
Cor a 9/Cor a 14 > 0.35 kUA/l n = 23 n = 8  
CD-sens, median (min-max) 0.02 (0–34.7) 8.9 (3.1–281) 0.0005 
Cor a 9/Cor a 14 > 2 kUA/l n = 8 n = 7  
CD-sens, median (min-max) 0.04 (0–0.2) 6.6 (4.7–281) 0.0012 
Table 5. CD-sens in relation to outcome in DBPCFC in patients with IgE-sensitization to Cor a 9/Cor a 14 above the 
two cut-points 0.35 and 2.0 kUA/l 
 
5.6.2 CD-sens in relation to adverse events 
As stated previously; if the patients had been clinically tolerant for ≥ 2 eight-week cycles, the 
omalizumab dose could be decreased despite a calculable (but non-increasing) CD-sens to peanut. For 
the vast majority of pOIT doses consumed, when the most recent CD-sens was calculable, no adverse 
events occurred. However, among the systemic reactions there were three moderate reactions in spite 
of the last CD-sens being negative to peanut, while 19 moderate and the only severe reaction occurred 
when the most recent CD-sens was positive. 
5.6.3 Long-term pOIT without omalizumab 
The eleven patients who successfully completed the FASTX study were invited to continue pOIT and 
participate in a follow-up study of pOIT for another three years. All 11 patients agreed and seven of 
them are still under pOIT while 4 have decided to stop the treatment. We have data from follow up 
visits after one year of OIT without omalizumab (n = 5) and after two years of OIT without 
omalizumab (n = 2). These five patients had very few adverse events throughout the FASTX study 
and they continue to tolerate the treatment well with a frequency of potential systemic reactions of 
around 1 per 2,000 doses. At the 1-year follow up, IgE-ab levels to both peanut and Ara h 2 had 
declined to below the baseline levels. Figure 13 shows changes in IgE-ab levels over time. 
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Figure 13. Total IgE and allergen-specific IgE-abs to peanut, Ara h 2 and control allergen for subjects completing 1 
more year of OIT after finishing the FASTX study (n = 5) and for those completing two additional years (n = 2). 
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6 DISCUSSION 
6.1 HAZELNUT ALLERGY DIAGNOSTICS STUDY 
The problem when diagnosing hazelnut allergy is the low specificity of the diagnostic tests, in 
particular among patients with birch pollen allergy, who often experience oral allergy syndrome upon 
ingestion of hazelnuts.
167-169
  
We showed that both CD-sens to hazelnut and component-resolved diagnostics with analysis of IgE-
abs to Cor a 9 and 14 were far superior in terms of specificity to the previously available serological 
tests for hazelnut allergy (IgE to hazelnut, Cor a 1) and this was without a trade-off to lost sensitivity 
(which is generally the case with diagnostic tests): all patients with a positive DBPCFC to hazelnut 
had a positive CD-sens and were IgE-sensitized to both Cor a 9 and Cor a 14 with IgE-ab levels above 
0.35 kUA/l. However, despite the perfect sensitivity of these tests in this study, there are several cases 
of hazelnut-allergic patients in other studies who are not sensitized to either Cor a 9 or Cor a 14, 
especially among adults.
15,17,104
  
Our data indicate that IgE-sensitization to Cor a 14 was superior to IgE-sensitization to Cor a 9 for 
correctly diagnosing hazelnut allergy, but this superiority was not statistically significant. Eller et al.
17
 
showed in a retrospective study that 94 % of challenge-positive children were sensitized to Cor a 9 or 
14, but importantly the remaining 6 % (4 patients) only had mild symptoms at the food challenge 
(OAS, lip swelling or localized urticaria). This study concludes that sensitization to Cor a 14 is the 
best diagnostic marker, although not significantly superior to Cor a 9; results from the US also 
indicate the superiority of Cor a 14.
170
 From the Netherlands, Masthoff et al. made a similar study to 
ours (however, this study also included adult patients); here, sensitization to Cor a 9 seemed to 
outperform sensitization to Cor a 14.
15
 This study also showed that 13 % of the allergic children and a 
majority of the adult allergic patients (55 %) were not sensitized to Cor a 9 or 14, but in a majority of 
the adults, the diagnosis was based on patient history alone (no challenge). However, there will always 
be outliers or exceptions from the diagnostic “rules” and they might be more common than expected. 
Kirsten Beyer et al. showed that the IgE-ab level to Cor a 14 corresponding to a 90 % probability of 
challenge proven hazelnut allergy was as high as 47.8 kUA/l (and for peanut allergy, the Ara h 2 level 
was 14.4 kUA/l).
104
 
So why are some patients with high-degree sensitization to Cor a 9 and Cor a 14 tolerant to hazelnuts? 
In our study, we observed a few hazelnut-tolerant patients with high IgE-ab levels to Cor a 9 or 14. 
Cross-reactivity might explain that some patients with high IgE-ab levels to Cor a 9 (but low Cor a 14) 
tolerated hazelnuts, as they had a verified peanut allergy with high IgE-ab titers to peanut and peanut 
components. A low allergen-specific IgE-abs/total IgE ratio might explain why some patients tolerate 
an allergen despite high IgE-levels to key components,
171
 as we observed in one patient who had an 
IgE-abs to Cor a 14 IgE of 13.9 but a total serum IgE of > 5,000 kU/l.  
6.1.1 CD-sens to hazelnut 
All patients with a positive hazelnut challenge were positive also in CD-sens; the allergic patients 
having a median CD-sens of 8.9 (5.2–41). The hazelnut-tolerant patients’ median level was 
substantially and significantly lower 0.05 (0.007–0.11) (P < .0001) and at the ROC-generated cut-off 
value of > 1.7, a 100 % sensitivity, 97 % specificity was reached for discrimination of 
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tolerance/subjective symptoms from objective symptoms at challenge. Of course, these results must be 
interpreted with great caution due to the small number of challenge-positive patients, especially when 
determining a cut-off value for clinical use. Elizur et al. analyzed BAT in children with allergies to 
one or more types of nuts (walnut, pecan, almond, cashew, pistachio, and hazelnut) and found that 
BAT was only superior to SPT when diagnosing hazelnut allergy; however, they used the CD-max 
method, not the CD-sens method.
172
 In a study of German adults, CD-sens (CD63-upregulation after 
stimulation with hazelnut) was significantly higher in patients with oral symptoms (or mild urticaria) 
or systemic symptoms compared with sensitized patients with no symptoms at all. But CD-sens could 
not discriminate patients with mild symptoms from those with systemic reactions.
173
  
In the patients with IgE-sensitization to Cor a 9/Cor a 14, CD-sens seems to be a valuable diagnostic 
tool as shown in the sensitivity analysis of CD-sens in this subgroup. Among hazelnut-tolerant 
patients with > 2 kUA/l of IgE-abs to Cor a 9 or 14 (n = 8), the median CD-sens to hazelnut was very 
low, 0.035 (the highest observed value was 0.2), while the lowest CD-sens among allergic patients 
was 3.07. Thus, it seems like CD-sens can be used as a complementary test when the diagnosis 
remains uncertain after using CRD.  
6.1.2 Strengths and limitations 
We performed DBPCFC on all subjects and these challenges were performed by experienced staff. 
Blood samples were drawn at the same day as the first challenge. With the rather small study 
population, the low proportion (20 %) of subjects reacting at DBPCFC became the main limitation. 
These results do not indicate that 80 % of patients with a doctor’s diagnosis of suspected hazelnut 
allergy are actually tolerant; our study population did not include patients who already had performed 
food challenges to hazelnut or patients with a history of moderate to severe anaphylaxis to hazelnut. It 
is also likely that the diagnostic accuracy in our study population (before DBPCFC) could have been 
improved by combining the results of SPT and analysis of IgE-abs to hazelnut and birch if these 
results were interpreted by a trained allergist.
41,87
  
6.1.3 Clinical implications 
In conclusion, both CRD and CD-sens facilitate hazelnut allergy diagnostics in children
15,17,90,170
 but it 
is still not perfect (the situation among adults remains even more complex
15,173
). While the specificity 
with these new diagnostic tests can be increased, there is still a risk of over-diagnosing hazelnut 
allergy if we do not analyze all data carefully. A two-step procedure with history and IgE-testing 
including CRD, followed by CD-sens in selected cases, could further improve the diagnostic accuracy 
and decrease false positive rates and/or the need of food challenges.  
6.2 PEANUT ORAL IMMUNOTHERAPY COMBINED WITH OMALIZUMAB 
In the FASTX studies we have corroborated previous findings of omalizumab’s potency in increasing 
peanut-allergic patients’ tolerance level to peanut. We have also showed that peanut oral 
immunotherapy can induce desensitization to peanut, but treatment is long and often troublesome.  
Omalizumab’s ability to increase food-allergic patients’ ability to tolerate the culprit foods has been 
proven in several studies.
36,37,39,40,138
 In these studies, the drug has been dosed either based on patient 
weight and total IgE or all patients received the same dose. Irrespective of dosing method, some 
patients remain very sensitive to peanuts, e.g., in the study by MacGinnitie et al. 4/27 patients could 
not reach a 250 mg peanut protein dose during rapid up-dosing after omalizumab
39
, and 1/9 patients 
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did not increase the tolerance to peanut at all, despite five months of omalizumab treatment in the 
study by Sampson et al.
37
 This was not observed in the FASTX study where all patients could ingest 
>800 mg peanut protein and we believe that this is at least partially due to the fact that 15/23 received 
an elevated dose of omalizumab. A dose-response correlation has previously been described for anti-
IgE-treatment,
138
 but since we did not perform food challenges before the dose was increased in these 
15 patients we cannot make a causal conclusion of the necessity to increase the dose in some patients. 
Our results also provide strong support for the protective effects of omalizumab during oral 
immunotherapy. The up-dosing went smoothly and rapidly in most patients; all 23 patients reached 
the maintenance dose of 10 g peanut in a median time of ten weeks. Our results can be compared with 
the results from pOIT studies without omalizumab but with similar study populations to ours; 
Blumchen et al.
129
 reported that 14/22 (64 %) patients reached a tolerated dose of 500 mg after seven 
months (median) of pOIT and four patients were excluded due to repeated allergic reactions, while 
Kukkonen et al.
174
 found that 33/39 (85 %) were able to reach the maintenance dose (4 peanuts) in a 
median of about nine months. MacGinnitie et al. compared pOIT and omalizumab with pOIT and 
placebo
39
 and they reported that there were fewer (but not significantly fewer) adverse events among 
omalizumab-treated patients; however, the omalizumab group consumed substantially higher doses of 
peanut. I am confident that if the pOIT doses had been matched, the difference in adverse events 
would have been more striking.
39
 The major disadvantage of using omalizumab as adjunctive therapy 
to OIT is its high price, ~1,000 €/month. While there are no studies on cost-effectiveness for 
omalizumab on this indication (though there are studies for asthma
175
), it seems highly unlikely that 
long-term treatment protocols would prove to be cost-effective. I think it is safe to conclude that 
omalizumab facilitates OIT, at least for patients with a severe allergy. Whether it also improves long-
term outcomes after the omalizumab treatment has been discontinued, for instance reducing AEs in 
OIT or achieving sustained unresponsiveness,
35
 is doubtful.
36,39
 
In total, 9/23 (39 %) of the patients in the our study met the primary end-point of tolerating pOIT at a 
dose of 2,800 mg of peanut for three months after discontinuation of omalizumab. Two more patients 
completed the protocol with a reduced pOIT (1,120/700 mg). We chose to include these two patients 
in the treatment success group for statistical analysis as the reason for dose-reduction was an 
abomination to the taste of peanuts, rendering an intention-to-treat success rate of 48 % (11/23). Per-
protocol success rates are often reported in clinical trials; however, in studies like FASTX, I believe 
that outcomes should be reported as ITT. In per-protocol analysis, drop-outs or patients not adhering 
to protocol are excluded from analysis. When a treatment is associated with side effects or is tough in 
other aspects, patients will adhere worse to treatment and some will stop it completely. Taking 
FASTX as an example, the per-protocol success rate (65 %) was markedly higher than the ITT 
success rate (48 %); however, for at least 4/6 of the drop-outs, it was adverse events (including an 
abomination to the taste of peanuts) that made them decide to discontinue the treatment.  
6.2.1 OIT vs. traditional AI (for allergies to pollen, pet, house dust mite etc.) 
Sub-cutaneous immunotherapy (SCIT) for, e.g., pollen allergy, has been practiced for over a century 
and is by now a widely accepted treatment. SCIT and later also SLIT are now widely implemented for 
the treatment of several types of allergies. When I have talked about our research and OIT I have often 
been asked questions like “Why does SCIT work so well, while OIT does not?” or “Why are there so 
many allergic reactions in OIT?” First of all, traditional AI is not effective in all patients and adverse 
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events do occur. Secondly, traditional AI has been gradually refined and improved over the past 
century, whereas OIT has only been tried in small trials in the last 10–15 years.  
AI mitigates allergies/allergic symptoms,
28
 and reduces development of asthma and new IgE-
sensitization in children.
176
 However, it is rarely completely curative, evidence for long-term effects is 
scarce and efficacy differs from one allergen to another.
177
 Severe adverse events are rare, but they do 
occur, with a frequency of adrenaline administration in the range of 0.1–0.2 % of SCIT doses28,178 
(comparable to the corresponding frequency in OIT
33,34
). However, since OIT is typically 
administered once daily, in contrast to roughly monthly injections in SCIT, the cumulative incidence 
of adverse events requiring epinephrine is higher in OIT. Table 6 makes a comparison of food OIT 
and SCIT for pollen allergy. 
 
OIT SCIT 
Likely not curative, increased tolerance allows for 
more liberal approach to eating out, attending parties 
where nuts are served etc.  Retained risk of having 
serious allergic reactions even after long-term OIT  
Most often not curative, reduction of symptoms can 
still be of value, milder symptoms, less medication  
Long treatment  Long treatment  
Daily dosing. Avoid physical activity for two hours 
following OIT dose EVERY day  
~Once a month.  
Worse compliance, forgotten or postponed doses due 
to, e.g., infections might affect long-term efficacy  
Minor adjustments to dose intervals most likely have 
no effect on long-term effects  
High cumulative incidence of adverse events  Low cumulative incidence of adverse events  
Adverse events occur at home  
Fewer visits to the clinic  
Adverse events occur at the clinic  
Monthly visits to the clinic  
No injections  Injections  
No natural boosters, ingestion has to continue (?) to 
sustain the increased tolerance  
For pollen or house dust mite allergy and similar, 
natural boosters (exposure) might prolong positive 
effects  
Long-term efficacy?  Long-term efficacy?  
Table 6. Comparison of OIT for food allergy and SCIT for pollen allergy. 
6.2.2 Oral immunotherapy; does it work? Is it worth it? 
Success rates for oral immunotherapy vary substantially from one study to another. Direct 
comparisons between studies are hampered by differences in study populations (age, severity of 
allergy), study protocols (duration, amount of peanut ingested, adjuvant treatments such as 
omalizumab,
39
 or antihistamines
174
), and outcomes (target dose, intention-to-treat vs. per-protocol). 
These differences are important, since current evidence suggests that patients with a more severe 
allergy (at least in terms of sensitization levels) respond worse to treatment,
35,36,179
 and that starting 
OIT at an early age seems to be beneficial.
70,119,180
 The difference is obvious when primary outcomes 
differ from tolerating small amounts
129
 to full servings.
35
 Also, many OIT studies report results when 
OIT has been given for a rather short period of time (6–12 months), which might lead to an 
  39 
underestimation of drop-out rates and hence an overestimation of the positive effects/tolerability of 
OIT. 
Despite this, there is now solid evidence that oral immunotherapy, in most patients, can induce an 
increased tolerance
119
 to several food allergens like egg,
130,181,182
, milk,
36,181,183,184
 and 
peanuts.
34,129,131,132,160,174,185
 OIT has also been tried for other foods like wheat
186,187
 and multiple 
foods.
188
 Although we need more evidence, I can see no theoretical reason why OIT should be less 
effective for other IgE-mediated food allergies. 
OIT can induce an increased tolerance, but it comes at a high price; patients going through OIT 
experience more systemic allergic reactions than those on avoidance diet.
189
 However, our personal 
experience from this study and previous work by our group
23
 and others
174
 indicate that the patients 
think it is a price worth paying. How can more allergic reactions and daily ingestion of (almost 
unanimously disliked) peanuts be preferred over continuing with strict avoidance? I think there are 
several reasons for this: being able to tolerate small amounts of the allergen allows a patient to eat at 
restaurants, cafés and parties without asking questions and having to worry. Even though systemic 
allergic reactions occur, they are to some extent expected and I believe that most of us handle setbacks 
or difficulties in life better if they were expected. 
6.3 OIT IN A NEAR FUTURE 
6.3.1 Important questions in OIT 
There are still many questions that need to be answered regarding OIT before it can be recommended 
as routine practice. 
Who should we treat with OIT? Patients with severe allergies will likely benefit more from a 
successful treatment; on the other hand, these patients seem to have significantly poorer 
outcomes.
35,179
 Severely allergic patients might benefit from omalizumab protection,
36
 but will this be 
cost-effective?  
For how long should OIT be given, and does it have to be administered daily? In studies 
evaluating sustained unresponsiveness after a couple of years of OIT, much of the increased tolerance 
was lost in a majority of patients after stopping OIT for weeks-months,
36,160,190
 but it seems that SU 
becomes more likely when treatment is longer.
190
 In the few published studies of long-term follow-up 
on OIT it appears that more liberal dosing schedules have been applied
130,191
 and, as I interpret these 
reports, this did not affect outcome. There is currently at least one study comparing different dosing 
schedules in long-term peanut OIT.
192
 
In which form should the food be ingested? Roasted peanuts, peanut flour and standardized 
(modified?) powder formulas (patented as a drug) have been tried. The cheapest, but least 
standardized, option would be to use peanuts straight from the grocery store, but one brand or type 
will differ from another when it comes to protein content, processing (roasting, degree of roasting) 
which will affect the allergenicity of the proteins. Boiled peanuts may decrease allergenicity while the 
ability of inducing protective immunological changes is maintained.
193
 
6.3.2 Improving OIT 
So far, OIT has shown potential as a disease-modifying treatment for food allergies, but we need to 
find methods to both increase the efficacy and decrease the number of adverse events before it can be 
implemented as routine practice at allergy clinics. Omalizumab has proven capable of reducing 
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adverse events in OIT, but it is an off-label treatment and hence it is unlikely that (the very high) costs 
will be covered by subsidies or health care insurances. One clinical implication is to seize the 
opportunity and start OIT in food-allergic patients who are treated with omalizumab for allergic 
asthma (but wait until the asthma is well-controlled). 
Another appealing idea is to start OIT early in life. A secondary prevention for peanut allergy among 
infants at risk, recently performed within the LEAP study,
70
 proved to be highly effective. Last year, 
very impressing results of pOIT in early childhood were reported by Vickery et al.
180
 They showed a 
78 % SU rate after a median of 2.5 years of OIT; additionally, no serious adverse events occurred, 
adrenaline was administered only once and the drop-out rate of 8 % was low in relation to the long 
treatment protocol. 
A third option to increase the efficacy and safety of OIT would be to develop modified OIT 
preparations, where we could learn from the science of vaccine development. Effective vaccines 
induce a strong but selective immune response, production of protective antibodies in the absence of 
symptoms of the disease (or mild symptoms only). By recombinant technology, protein structures can 
be altered so that a hypoallergenic (reduced IgE-binding properties), but normo-immunogenic (or 
ideally, a hyper-immunogenic) molecule is created.
194
 Conjugate extracts, e.g., with DNA sequences 
recognized by toll-like receptors
195,196
 or protein sequences mimicking virus proteins,
197
 are other 
appealing approaches that could be tried to improve OIT.  
Finally, the taste of peanuts seems to be a major problem, at least for our study subjects. If it would be 
possible to process peanuts or produce a peanut imitation by, e.g., recombinant techniques, so as to 
alter the taste, I am confident that compliance would improve and drop-out rates would be lower. 
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7 ETHICAL CONSIDERATIONS 
There are advantages and disadvantages to participation in medical studies. Table 7 lists potential 
advantages and disadvantages of participating in the FASTX study.  
Advantages Disadvantages 
Potential cure. If partial effect, protection from 
accidental exposure to small amounts of peanut. 
New treatment, will it work in our population? How long will 
the protection last? OIT-induced allergic reactions. 
Omalizumab ameliorates other IgE-mediated 
diseases (e.g., asthma and allergy to pollen). 
Painful injections. Risk of side effects from omalizumab. 
Blood samples drawn at several occasions. 
Easy access to pediatric allergists and nurse in 
the study team. Omalizumab treatment for 1–2.5 
years.  
Time-consuming, 20–50 hospital visits. Daily peanut 
consumption; most patients detested  the taste of peanuts. 
Cannot go on long trips > 4 weeks while on omalizumab. 
 Peanut challenge prior to inclusion: potentially dangerous 
and causing the patients a lot of emotional stress. 
Table 7. Advantages and disadvantages of taking part in the FASTX study. 
As with all demanding treatments, the disease itself has to cause a significant burden in order to make 
the treatment worthwhile. When presenting the study to the potential study subjects, I was surprised at 
how positive they were towards participation. Their fear of ingesting peanuts by mistake was almost 
always present, which clearly affected their quality of life. When presented with the facts, such as the 
long study protocol, frequent visits, uncertainty regarding outcome and risk of allergic reactions (most 
certainly during food challenge prior to inclusion), the patients and their parents were almost 
unanimously positive. In fact, when inclusion criteria were not met, patients and parents were very 
disappointed. However, when treating children and adolescents, we always have to remember that the 
patient’s wishes come first, not the parents’. Since parents of food-allergic children are often affected 
themselves, because of worries for their children, it is of utmost importance that we ascertain that the 
teenagers themselves want to take part in the study/therapy. I believe we tried to do this throughout the 
study. Most patients came to their visits alone, and if not, we tried to talk with them alone. During the 
long treatment period, some patients experienced difficulties with the therapy or life in general. 
During these times, we sometimes had a delicate task of encouraging our patients while not violating 
their voluntary study participation.  
By increasing their tolerance to peanuts, we will probably also have increased the patients’ quality of 
life. Patients with good or partial effect of OIT will also need fewer medical appointments, resulting in 
less need to be out of school/work. They will probably also need fewer drugs; these effects combined 
translate into economic benefits for the patient, families and society. 
The major drawbacks of the FASTX study were not the frequent visits, blood samples, and shots of 
omalizumab. Rather, they were the long study period, unexpected allergic reactions, and long-term 
psychological stress that some patients experienced while ingesting peanuts. The major advantage is 
the hope of curing an otherwise (most likely) life-long disease. If successful, this would allow a 
patient to live a life with fewer restrictions: to eat anything, anywhere, without worrying and not 
having to carry around emergency treatment kits. For patients with problematic rhino-conjunctivitis or 
asthma, omalizumab offers transient relief while on therapy, and this therapy would not be given to 
them otherwise due to the very high costs. 
Finally, in the bigger perspective, the results from the FASTX study and other studies on OIT or other 
types of AI for food allergy will help us to gradually improve the outcome of AI for food allergy by 
improving treatment protocols, selecting the right patients for treatment and finding strategies to 
minimize adverse events during therapy.
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8 CONCLUSIONS 
With the work performed in this thesis we believe that we have contributed to an improved situation 
for children and adolescents affected by an allergy to nuts or peanuts.  
 Component-resolved diagnostics can improve the accuracy when diagnosing hazelnut allergy 
in pediatric patients. 
 CD-sens to hazelnut may provide valuable additional information in cases when the 
diagnostic work-up using CRD has been inconclusive. 
 The anti-IgE-ab omalizumab can induce a pronounced decreased sensitivity to peanuts which 
in turn allows for a safer practice of peanut oral immunotherapy in severely allergic patients. 
 Peanut oral immunotherapy induces an increased tolerance to peanuts; the increased tolerance 
is at least partially explained by the production of protective allergen specific antibodies of 
IgG4-subtype. 
 Despite the increased tolerance, allergic reactions continuously occur during pOIT. We need 
to find ways to minimize this major limitation before OIT can be widely implemented. 
Development of hypoallergenic OIT preparations, use of immunostimulatory adjuvants, and 
improved patient selection might help in accomplishing a safer and more effective treatment. 
 44 
9 SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Förekomsten av allergi mot livsmedel har ökat under de senaste årtiondena och bland 
europeiska barn har närmare 8 % en allergi mot ett eller flera livsmedel. Men det finns också många 
barn som har fått en felaktig diagnos av matallergi på grund av brister i tillgängliga diagnostiska test, 
speciellt vid misstänkt allergi mot nötter eller jordnötter. Tack vare nya diagnostiska test, som 
komponent-diagnostik (CRD) och CD-sens har de diagnostiska möjligheterna förbättrats. 
Den allvarligaste akuta reaktionen vid allergi, anafylaktisk reaktion, är bland svenska barn oftast 
orsakad av en allergi mot jordnötter eller nötter. För dessa svårt matallergiska patienter har det inte 
funnits någon tillgänglig behandling med möjlighet att förändra sjukdomsförloppet. Allergen 
immunterapi (hyposens/allergivaccination) har sedan länge erbjudits som behandling av patienter med 
uttalad pollenallergi eller allergi mot getingstick. Patienter med svåra matallergier har istället fått 
försöka undvika det de är allergiska mot och om olyckan skulle vara framme; använda de 
akutmediciner som dessa patienter ständigt bär med sig. Sedan 10-15 år har oral immunterapi (OIT) 
framkommit som en potentiell behandling för matallergier. Vid OIT äter patienten mycket små, men 
gradvis ökande doser av livsmedlet som framkallar allergisk reaktion varvid en ökad tolerans byggs 
upp. I de studier som är gjorda på OIT har allergiska reaktioner varit vanliga och patienter med en 
allvarligare allergi svarar sämre på behandlingen. OIT-metoden behöver förfinas innan den kan 
införas på bredare front som en behandling av matallergi. Läkemedlet omalizumab (anti-IgE-
antikroppar) har visat sig kunna minska känsligheten för födoämnen bland allergiska patienter och kan 
underlätta OIT. 
Mål: Hasselnötsstudien: Att utvärdera de nya diagnostiska testen CRD och CD-sens hos barn med en 
misstänkt hasselnötsallergi. FASTX-studien: Att utvärdera säkerhet och effekt av oral immunterapi 
med omalizumab som skyddande tilläggsbehandling bland allvarligt jordnötsallergiska ungdomar. 
Metoder: I hasselnötsstudien mätte vi IgE-antikroppar mot hasselnötskomponenterna Cor a 1, Cor a 8, 
Cor a 9 och Cor a 14 hos 40 barn med en misstänkt hasselnötsallergi. Vi utvärderade också basofil 
allergenkänslighet (CD-sens) för hasselnöt och jämförde utfallen av dessa test med utfallen i 
hasselnötsprovokationer.  
I FASTX-studien gavs omalizumab till 23 ungdomar med svår jordnötsallergi vilket syftade till att 
minska känsligheten mot jordnötter så att OIT kunde ges under säkrare former. Omalizumab titrerades 
vid behov upp till dess att CD-sens visade en utsläckt eller mycket låg reaktivitet mot jordnöt. Därefter 
genomfördes en jordnötsprovokation, där den minskade känsligheten mot jordnötter utvärderades. 
Jordnöts-OIT startades följande dag under fortsatt skydd av omalizumab. Efter att ha nått 
underhållsdosen på 10 g jordnötter så trappades den skyddande omalizumab-behandlingen successivt 
ned, med vägledning från CD-sens och den kliniska bilden. 
Resultat: Hasselnötsprovokationerna visade att endast 8/40 av patienterna med en misstänkt 
hasselnötsallergi var allergiska mot hasselnötter. Träffsäkerheten hos de nya diagnostiska testen, CD-
sens och komponentdiagnostik med IgE-antikroppar mot Cor a 9 och Cor 14, var överlägsen de 
tidigare tillgängliga testen (IgE-ab till hasselnöt, Cor a 1 och Cor a 8). Alla hasselnötsallergiska 
patienter hade IgE-ak mot Cor a 9 och Cor a 14.  
CD-sens bland patienter allergiska mot hasselnöt var i median 8,9 jämfört med 0,05 hos toleranta 
patienter (P = 0,05).  
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Efter behandling med omalizumab klarade alla 23 patienter en jordnötsprovokation där de åt 
åtminstone 3 g jordnötter (median 10 g). Bland de 14 patienter som även genomgick en 
jordnötsprovokation före studiestart ökade den tolererade dosen 50 gånger (median). Dock krävde 
15/23 patienter en ökad dos av omalizumab för att åstadkomma den hämning av CD-sens som krävdes 
för att de skulle få göra provokationen. Alla 23 patienter nådde framgångsrikt underhållsdosen på 10 g 
jordnötter. Efter 23 månader (median) med OIT hade 11/23 (48 %) av försökspersonerna kunnat 
avsluta omalizumab-behandlingen medan de fortsatte OIT och kunde därefter framgångsrikt genomgå 
en ny jordnötsprovokation. Systemiska allergiska reaktioner förekom med en frekvens av 0,3 % av 
OIT-doserna (n = 43) och adrenalin gavs efter 0,1 % av doserna. De patienter som var framgångsrikt 
behandlade hade signifikant lägre CD-sens och lägre nivåer av IgE-ak mot jordnöt- och 
jordnötskomponenterna Ara h 1, Ara h 2 och Ara h 3 vid studiestart jämfört med patienter som inte 
kunde avbryta den skyddande omalizumab-behandlingen. OIT gav en ökning av skyddande IgG4-ak 
mot jordnöt, Ara h2 och Ara h 6 som var signifikant högre hos framgångsrikt behandlade patienter. 
Sex av de 23 patienterna hoppade av studien, främst på grund av rädsla för allergiska reaktioner och 
en avsky för smaken av jordnötter.  
Slutsatser: CD-sens mot hasselnöt och komponentdiagnostik kan förbättra träffsäkerheten vid 
diagnostik av hasselnötsallergi hos barn.  
Omalizumab-behandling ger en uttalat sänkt känslighet för jordnötter hos ungdomar med svår 
jordnötsallergi vilket i sin tur ger förutsättningar för att genomföra OIT under säkrare former. Den 
minskade känsligheten förklaras åtminstone delvis av produktionen av skyddande allergenspecifika 
antikroppar av IgG4-subtyp. 
Trots den ökade toleransen uppstår allergiska reaktioner kontinuerligt under OIT. Innan OIT kan 
implementeras i större utsträckning måste vi hitta sätt att minimera behandlingsrelaterade allergiska 
reaktioner. Hypoallergena OIT-preparat, användning av immunstimulerande tilläggsbehandlingar och 
att hitta sätt att välja ut patienter med högre sannolikhet för positivt behandlingssvar kan vara sätt att 
åstadkomma detta. 
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